Peposertib Phase Ib/II study of peposertib in combination with capecitabine and
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N3/122Section # and Name [CONTACT_250017].
Removed the row for protocol 
previous version.Required and/or 
recommended changes per [COMPANY_006] Protocol Template 
version 15.
Section 5 Study Population
Appendix 2 Study GovernanceIncluded mandatory text 
regarding participant’s legal representative.
Removed the definition of “legally 
authorized representative” from Appendix 2.
Section 1.1 Synopsis
Section 1.2 SchemaSection 1.3 Schedule of ActivitiesSection 2.3 Benefit/Risk AssessmentSection 3 Objectives and EndpointsSection 3.1 Definitions of Pathological 
Complete Response and Clinical Complete Response, and Derivation of the Composite Endpoint
Section 4.1 Overall DesignSection 4.1.2 Treatment PeriodSection 4.1.3 Follow-up PeriodsSection 4.2 Scientific Rationale for Study
Design
Section 5.4 Screen FailuresSection 6.1 Study Intervention(s) AdministrationSection 6.3.1 Study Intervention AssignmentSection 6.3.2 BlindingSection 6.3.3 Emergency Unblinding (Section 
removed)
Section 6.6 Dose Selection and ModificationSection 6.6.2 Dosing Instructions (and 
subsections)
Section 8 Study Assessments and ProceduresSection 8.1.1 Pathological Complete ResponseSection 8.1.2 Tumor Evaluation Methods and 
Response Assessment
Section 8.1.3 Quality of Life (Section removed)Section 8.2.3 ElectrocardiogramsSection 8.5 Pharmacokinetics
Section 9.3 Population for Analyses
Section 9.4 Statistical AnalysesSection 9.4.1 Efficacy AnalysesSection 9.4.2 Safety AnalysesSection 9.4.3 Other AnalysesSection 9.4.4 Sequence of AnalysesAppendix 2 Study GovernanceAppropriate details of Phase II 
part of the study removed from the protocol in the respective 
sections.Study will be prematurely 
discontinued. Participants in Phase Ib will only be 
followed for 1 year, Phase II 
will not be started (see overall rationale above).
CCI
CCICCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N4/122Section # and Name [CONTACT_19523] 1.1 Synopsis
Section 1.2 SchemaSection 1.3 Schedule of ActivitiesSection 3 Objectives and EndpointsSection 4.1 Overall DesignSection 4.1.3 Follow-up Periods
Section 6.5 Concomitant Therapy
Section 8.1.2 Tumor Evaluation Methods and 
Response Assessment
Section [IP_ADDRESS] Tumor Response Evaluation
Section 8.2 Safety Assessments and
Procedures
Section 8.3.1 Time Period and Frequency for 
Collecting Adverse Event and Serious Adverse Event Information
Section 8.3.3 Follow-up of Adverse Events and 
Serious Adverse Events
Appendix 5 Tumor Response CriteriaLong-term Safety Follow-up 
period shortened to 1 year (previously 2 years) and 
removed Survival Follow-up.Safety Follow-up is reduced 
to [ADDRESS_303802] year after 
treatment.
Section 1.1 Synopsis
Section 3 Objectives and EndpointsSection 9.4.1 Efficacy AnalysesRemoved the endpoints of 
“overall survival” and “best overall response”.Overall survival removed as 
the Safety Follow-up period is reduced to 1 year. 
Section 1.1 Synopsis
Section 3 Objectives and Endpoints
Section 9.4.1 Efficacy AnalysesAdded endpoint of “neoadjuvant 
rectal score”.Due to discontinuation of 
Phase II, data on the neoadjuvant rectal score of Phase Ib will be analyzed to obtain more comprehensive 
data on antitumor activity.
Section 6.1 Study Intervention(s) Administration Added that “for Spain, 
capecitabine will be provided by [CONTACT_249974]”.To clarify the Supplier 
details of capecitabine in Spain.
Throughout Minor editorial and document 
formatting revisions.Minor; therefore, have not 
been summarized.
- Confidential –
This document is the property of [COMPANY_006] KGaA, Darmstadt, [LOCATION_013], or one of its subsidiaries. It is intended for 
restricted use only and may not – in full or part – be passed on, reproduced, published or used without express 
permission of [COMPANY_006] KGaA, Darmstadt, [LOCATION_013], or its subsidiary. Copyright © 2021 by [CONTACT_28794], Darmstadt, 
[LOCATION_013], or its subsidiary. All rights reserved.
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N5/122Table of Contents
Title Page ..............................................................................................................[ADDRESS_303803] of Figures ..............................................................................................................9
1 Protocol Summary ..............................................................................11
1.1 Synopsis..............................................................................................111.2 Schema................................................................................................131.3 Schedule of Activities.........................................................................142 Introduction.........................................................................................31
31
2.2 Background.........................................................................................312.3 Benefit/Risk Assessment ....................................................................333 Objectives and Endpoints ...................................................................353.1 Definitions of Pathological Complete Response and Clinical 
Complete Response, and Derivation of the Composite Endpoint ......36
4 Study Design.......................................................................................384.1 Overall Design ....................................................................................384.1.1 Screening Period.................................................................................384.1.2 Treatment Period ................................................................................384.1.3 Follow-up Periods...............................................................................394.2 Scientific Rationale for Study Design ................................................394.3 Justification for Dose..........................................................................404.4 End of Study Definition......................................................................415 Study Population.................................................................................415.1 Inclusion Criteria ................................................................................425.2 Exclusion Criteria ...............................................................................445.3 Lifestyle Considerations .....................................................................455.3.1 Meals and Dietary Restrictions...........................................................455.3.2 Caffeine, Alcohol, and Tobacco .........................................................455.3.3 Activity ...............................................................................................465.4 Screen Failures....................................................................................46
CCI
CCICCI CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N6/1226 Study Intervention(s) ..........................................................................46
6.1 Study Interventi on(s) Administration.................................................46
6.2 Study Intervention(s) Preparation, Handling, Storage, and 
Accountability.....................................................................................47
6.3 Measures to Minimize Bias: Study Intervention Assignment and 
Blinding ..............................................................................................49
6.3.1 Study Intervention Assignment ..........................................................496.3.2 Blinding ..............................................................................................496.4 Study Intervention Compliance ..........................................................496.5 Concomitant Therapy .........................................................................506.5.1 Prohibited Medicines..........................................................................506.6 Dose Selection and Modification........................................................516.6.1 Definition of Dose Limiting Toxicity.................................................516.6.2 Dosing Instructions.............................................................................[IP_ADDRESS] Peposertib ...........................................................................................[IP_ADDRESS] Capecitabine .......................................................................................[IP_ADDRESS] Radiotherapy.......................................................................................[IP_ADDRESS] Administration of the Combination Therapy......................................546.6.3 Management of Toxicities ..................................................................[IP_ADDRESS] Diarrhea ..............................................................................................[IP_ADDRESS] Capecitabine Management for Toxicities Other Than Diarrhea.........[IP_ADDRESS] Peposertib and Radiotherapy ..............................................................[IP_ADDRESS] Radiotherapy Treatment Delay...........................................................596.[ADDRESS_303804]........................................597 Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal...............................................................60
7.1 Discontinuation of Study Intervention................................................607.1.1 Temporary Discontinuation................................................................607.1.2 Rechallenge.........................................................................................607.2 Participant Discontinuation/Withdrawal from the Study ...................617.[ADDRESS_303805] to Follow-up ...............................................................................61
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N7/1228 Study Assessments and Procedures....................................................62
8.1 Efficacy Assessments and Procedures................................................638.1.1 Pathological Complete Response .......................................................638.1.2 Tumor Evaluation Methods and Response Assessment .....................[IP_ADDRESS] Evaluation Methods............................................................................[IP_ADDRESS] Tumor Response Evaluation...............................................................[IP_ADDRESS] Neoadjuvant Rectal Score...................................................................658.2 Safety Assessments and Procedures ...................................................668.2.1 Physical Examinations........................................................................668.2.2 Vital Signs ..........................................................................................678.2.3 Electrocardiograms .............................................................................678.2.4 Clinical Safety Laboratory Assessments ............................................678.2.5 Suicidal Risk Monitoring....................................................................688.3 Adverse Events and Serious Adverse Events .....................................688.3.1 Time Period and Frequency for Collecting Adverse Event and 
Serious Adverse Event Information....................................................68
8.3.2 Method of Detecting Adverse Events and Serious Adverse Events...688.3.3 Follow-up of Adverse Events and Serious Adverse Events ...............688.3.4 Regulatory Reporting Requirements for Serious Adverse Events .....698.3.5 Pregnancy ...........................................................................................698.4 Treatment of Overdose .......................................................................708.5 Pharmacokinetics................................................................................70
727273
8.9 Health Economics...............................................................................74
74
9 Statistical Considerations....................................................................749.1 Statistical Hypotheses.........................................................................749.2 Sample Size Determination ................................................................749.3 Populations for Analyses ....................................................................749.4 Statistical Analyses.............................................................................75
CCI
CCICC
ICCI
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N8/1229.4.1 Efficacy Analyses ...............................................................................75
9.4.2 Safety Analyses ..................................................................................769.4.3 Other Analyses....................................................................................789.4.4 Sequence of Analyses .........................................................................7910 References...........................................................................................8011 Appendices .........................................................................................83Appendix 1 Abbreviations......................................................................................84Appendix 2 Study Governance...............................................................................86
Appendix 3 Contraception......................................................................................93Appendix 4 Radiation Therapy ..............................................................................95Appendix 5 Tumor Response Criteria....................................................................98Appendix 6 Pathology Assessments.....................................................................100Appendix 7 Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow-up, and Reporting..............................................103
Appendix 8 Clinical Laboratory Tests .................................................................107
.108
Appendix 10 Model for Bayesian Dose Escalation................................................109Appendix 11 Protocol Amendment History...........................................................112Appendix 12 Sponsor Signature [CONTACT_3490] ....................................................................120Appendix 13 Coordinating Investigator [INVESTIGATOR_24026]........................................121Appendix 14 Principal Investigator [INVESTIGATOR_24026]...............................................122
CCI
CCICCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N10/122Figure 4 Prior Distribution..............................................................................110
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N11/1221 Protocol Summary
1.1 Synopsis
Protocol Title: A multicenter study with an open-label Phase Ib part followed by a randomized, 
placebo-controlled, double-blind, Phase II part to evaluate efficacy, safety, tolerability, and 
pharmacokinetics of the DNA-PK inhibitor peposertib (M3814) in combination with capecitabine and radiotherapy in participants with locally advanced rectal cancer.
Short Title: Phase Ib/II study of peposertib in combination with capecitabine and radiotherapy in 
rectal cancer.
Phase II of this study will not be performed and was therefore deleted from this protocol.
Objectives and Endpoints:
Objectives Endpoints (Outcome Measures) Endpoints (Outcome Measures) 
Timeframe
Primary
To define a maximum tolerated 
dose (MTD) and recommended Phase II dose (RP2D) of peposertib in combination with capecitabine and RTOccurrence of dose limiting 
toxicities (DLTs)Time from first study intervention 
to the end of chemoradiotherapywith a final assessment at 4 weeks after surgery
Secondary
To evaluate safety and tolerability of peposertib in combination with capecitabine and RT!Occurrence of 
treatment-emergent adverse events (TEAEs) and 
treatment-related adverse 
events according to the National Cancer Institute (NCI)-Common Terminology Criteria of Adverse 
Events (CTCAE) version 5.0
!Occurrence of abnormalities 
(Grade≥3) in laboratory test 
values, markedly abnormal vital sign measurements, and 
clinically significantly abnormal 
electrocardiograms (ECGs)including clinically important increases in QT interval (QTcF)Time from first study intervention 
to final assessment at 1 year
CCI
CCICCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N12/122Objectives Endpoints (Outcome Measures) Endpoints (Outcome Measures) 
Timeframe
To explore antitumor activity of 
peposertib in combination with capecitabine and RT!Composite endpoint of pCR/cCR !Pathology evaluation of
specimen after surgery (pCR) and clinical evaluation 1 to 2 weeks prior to surgery 
(cCR)
!Disease-free Survival !Time from first study
intervention to final
assessment at 1 year
!pCR !Pathology evaluation of
specimen after surgery
!cCR !Time from first study
intervention until clinical 
evaluation 1 to 2 weeks prior 
to surgery
!Local recurrence and/or distant
metastasis!Time from surgery to final
assessment at 1 year
!Neoadjuvant rectal score !Pathology evaluation of 
specimen after surgery
To assess the pharmacokinetics(PK) of peposertibPharmacokinetic profile of 
peposertib in terms of PK parameter estimates (e.g. C
max, AUC 0-t, tmax, 
CL/f, Vz/f, and t 1/2)Fraction day (FD)1 and FD9
Overall Design: This is a multicenter, open-label, single arm, dose escalation study in participants 
with locally advanced rectal cancer.
The study will consist of a Screening period of 4 weeks, a Treatment period of 5 to 5.5 weeks (25 
or 28 FD) (DLT period), a Short-term Safety Follo w-up period of 13.5 weeks (including 30 days 
after surgery), a Long-term Safety Follow-up period until 1 year after the start of study intervention/randomization.
Number of Participants: The planned cohort size is 3 participants. The total sample size will 
depend on the number of cohorts to be evaluated. It is anticipated that 18 to 30 evaluable participants will be required.
Study Intervention Groups and Duration: Participants will be assigned to peposertib given in 
combination with capecitabine 825 mg/m
2twice daily 5 days/week and RT of 50 to 50.4 Gy to the 
tumor area and 45 Gy to the electively irradiated tissues in 25 or 28 fractions (corresponding to 5to 5.5 weeks). The starting dose of peposertib for the first cohort will be 50 mg once daily5 days/week. The peposertib dose for the next cohorts will be determined by [CONTACT_28749] (SMC) guided by a Bayesian 2-parameter logistic regression model with overdose control.
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N13/122Premature Discontinuation: As of [ADDRESS_303806] finished the study up 
to Week 19 as well as changing treatment landscap e in locally advanced rectal cancer indicate that 
the ability to generate a meaningful proof of concept under the current protocol is low. Therefore, the dose escalation in the Phase Ib part will be prematurely discontinued after completing the Cohort 5 of 150 mg, and the Phase II part of the study will not be initiated.
Involvement of Special Committee(s): Yes
1.2 Schema
Figure 1 shows a schematic overview of the study design.
Figure 1 Study Design Diagram
DLT=dose limiting toxicity, Gy=Gray, FU=follow-up, RP2D=recommended Phase II dose, RT=radiotherapy.
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N14/1221.3 Schedule of Activities
The treatment period will include 25 or 28 RT fractions, depending on local practice.
!The Schedule of Activities (SoA) is provided in  Table 1.
!The SoA for the Long-term Safety Follow-up is provided in  Table 2.
!
!The PK sampling schedule is provided in  Table 4.
!
CCI
CCICCICCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and radiotherapy in rectal cancer
MS100036-0020
C O N F I D E N T I A L
I N F O R M A T I O N26/122Table 2 Schedule of Activities – Long-term Safety Follow-up Period
Study Periods Long-term Safety FU Notes
Visit Weeks 19 to 52
Visit Week21 and 27 wk after start of study intervention/ 
randomization: Wk 21 and 27; thereafter every 
3 mo in Yr 1: Wk 39 and 52Participants followed-up until 1 year after start of study 
intervention/randomization, or earlier due to any reason whereby [CONTACT_249975] (e.g. if new treatment is started, study discontinued, withdrawal of consent). Adjuvant chemotherapy is allowed as 
per local standards (see Section 6.5). Participants receiving adjuvant 
chemotherapy will continue to follow the schedule of activities as per protocol. If adjuvant chemotherapy is given any additional safety evaluations/laboratory tests will be as per local practice.
Reason for early discontinuation should be captured in source documents. If 
EOT occurs before Wk 52, all assessments must be done as planned for 
Wk 52. 
Visit Windows (Week)± 1 for Wk 21;
± [ADDRESS_303807] already been followed up for more than 1 year (Long-term Safety or Survival Follow-up) will be discontinu ed from the study after the 
approval of protocol amendment version 4.0 by [CONTACT_249976]. Participants will be informed o f the discontinuation by [CONTACT_249977] a phone call. No further study visits or assessments are planned.
Assessment and Procedures
Vital Signs X Pulse rate, DBP, SBP, body temperature, and body weight.
Physical Examination XPhysical examination (including body weight) will report findings in the 
irradiated area during Short- and Long-Term FU periods.
ECOG PS X
Adverse Event AssessmentXEvaluation of ongoing or new AEs assessed as related to study intervention 
until resolution or permanent outcome. New SAE assessed as unrelated to study intervention only up to Wk 27.
Concomitant Therapy X
Adjuvant Chemotherapy XAdjuvant chemotherapy if given, according to local guidelines, must start 
between 1 and 3 mo after surgery.
Hematology X
Serum Chemistry and CoagulationX
'RFXPHQW1R
2EMHFW1RCCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and radiotherapy in rectal cancer
MS100036-0020
C O N F I D E N T I A L
I N F O R M A T I O N27/122Study Periods Long-term Safety FU Notes
Visit Weeks 19 to 52
Visit Week21 and 27 wk after start of study intervention/ 
randomization: Wk 21 and 27; thereafter every 
3 mo in Yr 1: Wk 39 and 52Participants followed-up until 1 year after start of study 
intervention/randomization, or earlier due to any reason whereby [CONTACT_249975] (e.g. if new treatment is started, study discontinued, withdrawal of consent). Adjuvant chemotherapy is allowed as 
per local standards (see Section 6.5). Participants receiving adjuvant 
chemotherapy will continue to follow the schedule of activities as per protocol. If adjuvant chemotherapy is given any additional safety evaluations/laboratory tests will be as per local practice.
Reason for early discontinuation should be captured in source documents. If 
EOT occurs before Wk 52, all assessments must be done as planned for 
Wk 52. 
Visit Windows (Week)± 1 for Wk 21;
± [ADDRESS_303808] already been followed up for more than 1 year (Long-term Safety or Survival Follow-up) will be discontinu ed from the study after the 
approval of protocol amendment version 4.0 by [CONTACT_249976]. Participants will be informed o f the discontinuation by [CONTACT_249977] a phone call. No further study visits or assessments are planned.
Assessment and Procedures
Carcinoembryonic 
AntigenX
MRI/CT X (starting Wk 27)T2weighted and diffusion weighted, without gadolinium. No MRI/CT at 
Wk 21.
AE=adverse event, CT=computerized tomography, ctDNA=circulating tumor DNA, DBP=diastolic blood pressure, ECOG PS=Eastern Cooperati ve Oncology 
Group Performance Status, EOT=End of Trial, FU=Follow-up, MRI =magnetic resonance imaging, SAE=serious adverse event, SBP=systolic b lood pressure.
'RFXPHQW1R
2EMHFW1RCCI
CCICCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and radiotherapy in rectal cancer
MS100036-0020
C O N F I D E N T I A L
I N F O R M A T I O N28/122
'RFXPHQW1R
2EMHFW1RCCI
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and radiotherapy in rectal cancer
MS100036-0020
C O N F I D E N T I A L
I N F O R M A T I O N29/122Table 4 Pharmacokinetic Sampling Schedule of Peposertib and Capecitabine
Study 
DaySampling Time Point 
(Peposertib) Sampling Window Phase Ib Notes
FD1 Predose Within 60 min prior to 
peposertib 
administrationX Predose samples should be taken before capecitabine and 
peposertib administration. All other sampling times are 
related to peposertib administration; sampling for 
capecitabine/metabolite PK is done at the same time as the blood is drawn for peposertib PK analysis1h ±1 0m i n X
2h ±1 0m i n X
3h ±2 0m i n X
4h ±2 0m i n X
6h ±3 0m i n X
FD2 Predose Within 60 min prior to 
peposertib 
administrationX Predose samples should be taken before capecitabine and 
peposertib administration.
FD9 Predose Within 60 min prior to 
peposertib 
administrationX Predose samples should be taken before capecitabine and 
peposertib administration. All other sampling times are related to peposertib administration; sampling for capecitabine/metabolite PK is done at the same time as the blood is drawn for peposertib PK analysis
1h ±1 0m i n X
2h ±1 0m i n X
3h ±2 0m i n X
4h ±2 0m i n X
6h ±3 0m i n X
FD10 Predose Within 60 min prior to 
peposertib 
administrationX Predose samples should be taken before capecitabine and 
peposertib administration.
FD=fraction day, PK=pharmacokinetics.
'RFXPHQW1R
2EMHFW1RCCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and radiotherapy in rectal cancer
MS100036-0020
C O N F I D E N T I A L
I N F O R M A T I O N30/122
'RFXPHQW1R
2EMHFW1RCCI
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N32/122completed the single dose escalation part where 31 participants were treated with dose levels 
between 100 mg once daily and 400 mg twice daily. The max imum tolerated dose (MTD) was not 
reached at 400 mg twice daily; however, further dose escalation was not done, per Safety Monitoring Committee (SMC) decision. There were no dose limiting toxicities (DLTs) reported at the 400 mg twice daily dose level. The recommended Phase II dose (RP2D) for peposertibmonotherapy was established as 400 mg twice daily and confirmed in an additional 6 aspi[INVESTIGATOR_248]-naïve participants (aspi[INVESTIGATOR_248]-naïve participants were included to test for alterations in platelet aggregation). The efficacy data did not support further develop ment of peposertib in monotherapy due to the 
lack of clear clinical activity in this setting.
The second study with peposertib (EMR100036-002) is currently ongoing and is a combined 
Phase Ia/Ib, open label, dose escalation and dose-expansion study designed to explore the safety, tolerability, PK,  and clinical activity of peposertib in combination with RT/chemoradiotherapy (CRT), and to determine the MTD and a RP2D for peposertib in combination with RT/CRT.
!The Arm A-Phase Ia part of the study includes previously treated participants with locally advanced disease (any tumor or metastases including lymphomas) localized in the head and neck region or thorax that is not amenable to s urgical therapy or with standard systemic therapy 
with an indication for palliative RT (30 Gy in 10 fractions) over 2 weeks. 
!The Arm B-Phase Ia part includes treatment naïve SCCHN participants who are eligible for fractionated RT (66 to 70 Gy in 33 to 35 fractions) with concurrent cisplatin.
!In ancillary clinical proof-of-principle part of the study, participants with at least 2 cutaneous/subcutaneous tumors/metastasis are included to evaluate alterations in phosphorylated-DNA-PK expression induced by [CONTACT_937] (Lesion 1), as compared with expression 
induced by [CONTACT_249978] (Lesion 2).
A third study (MS100036-0022) investigated peposertib in combination with etoposide and 
cisplatin in participants with treatment naïve extensive disease SCLC. Two participants were treated with peposertib (capsule and tablet formulation). One participant received a single dose of the tablet, and the capsule for the remainder of th e study. No DLTs or deaths were reported, and 
none of the participants discontinued due to an adverse event (AE). Enrollment in the study was prematurely terminated due to recruitment challenges and not due to concerns of safety for the subjects. 
The Investigator’s Brochure provides a more detailed overview of the nonclinical and clinical 
information on peposertib.
Rectal cancer is a subset of colorectal cancer, which  is the third most common diagnosed cancer. 
An estimated 40,000 new cases of rectal cancer were diagnosed in 2017 in the [LOCATION_003] with an increase in incidence rates in the younger population (Siegel 2017) . In the European Union the 
incidence of rectal cancer is 15 to 25 cases/100, 000 population per year resulting in approximately 
125,000 new cases per year, and mortality is 4-10/100,000 population per year (Glynne-Jones 2017) . Rectal cancer is a distal large bowel adenocarcinoma tumor located at or 
below the peritoneal reflection. The standard of care (SoC) for locally advanced rectal cancers is neoadjuvant CRT, with or without sequential chemotherapy followed by [CONTACT_249979] (e.g.
CCI
CCICCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N33/122total mesorectal excision [TME]), with the aim to remove the irradiated tumor and decrease the 
risk of local recurrence and mortality (National Comprehensive Cancer Network® [NCCN] Guidelines for Patients® Rectal Cancer 2019;  Glynne-Jones 2017) . This methodology has resulted 
in a decrease in local recurrence and an improvement in mortality rates (Shahab 2017) . However, 
one-third of patients with locally advanced rectal cancer will later develop distant metastases and will subsequently die from the disease. In addition, most survivors experience significant impairment in their QoL, due primarily to removal of the rectum. Consequently, the current challenges in the treatment of locally advanced rectal cancer are how to improve survival by [CONTACT_249980], and how to improve QoL in surviving patients by [CONTACT_249981]. There is an unmet need to improve long-term outcomes and QoL and so the development of new therapeutic strategies to further increase these aspects is of key importance.
2.3 Benefit/Risk Assessment
The benefit-risk relationship has been carefully considered in the planning of this study. Nonclinical data show that peposertib potently a nd selectively inhibits DNA DSB repair induced 
by [CONTACT_249982].
As of 18 December 2019 (Investigator’s Brochure, Version 8.0), the important potential risks with
peposertib identified for the purpose of the study based on nonclinical studies are as follows:
!Lymphoid depletion with risk of infection
!Stomatitis, mucositis
!Rash
!Increased radiation dermatitis
!Reproductive toxicity
!Increase in liver enzymes: aspartate aminotransferase, alanine aminotransferase and glutamate dehydrogenase
!Drug-drug interactions
Further, the following not important potential risks have been identified:
!Vomiting
!Diarrhea 
There are no other important potential risks from completed/ongoing studies that are considered 
relevant for this rectal study population.
Recommendations for the clinical use of peposertib include the monitoring of adverse effects in 
the digestive tract and radiation side effects, as well as monitoring of hematological parameters and liver enzymes. In addition, precautionary measures to mitigate the risks of other treatments 
and treatment recommendations of known adverse reactions, need to be respected when given in combination with peposertib.
More detailed information about the known and expected benefits and risks and reasonably 
expected AEs of peposertib may be found in Section 4.2(Scientific Rationale for Study Design)
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N34/122and the Investigator’s Brochure, Participant Information Leaflet, or Development Safety Update 
Report.
The purpose of this study is to determine whether peposertib can be safely administered in 
combination with the current neoadjuvant SoC for rectal cancer, capecitabine in combination with RT, and whether the combination with peposertib shows a relevant antitumor efficacy advantage 
compared with SoC. Improved rates of clinical complete response (cCR) should translate into higher rates of organ preservation in patients with locally advanced rectal cancer. It is hypothesizedthat this will improve long-term QoL outcomes.
In this study, appropriate precautionary measures to mitigate the potential risks are implemented. 
The safety will be monitored on an ongoing basis by [CONTACT_4484]. The study will be discontinued in the event of any new findings that indicate a releva nt deterioration of the benefit-risk balance for 
the participants, which would render continuation of the study unjustifiable.
The SoC CRT has a known and well-established toxicity profile. Nausea, vomiting, diarrhea, 
mucositis, hand-foot syndrome, radiation dermatitis, and decreases in hemoglobin, leucocytes, and platelets, are the most frequently reported Grade 3 AEs in clinical studies with capecitabine and RT (Liu 2016) . These potential toxicities can be readily monitored with clinical laboratory, AE,
and clinical assessments.
It is known that RT can cause acute toxicities in the form of, e.g. radiation dermatitis and mucositis. 
Late toxicities arising [ADDRESS_303809] of the study, as specified 
in this protocol, is considered justifiable.
The starting dose of 50 mg once daily peposertib in combination with RT and capecitabine is 
considered appropriate to mitigate possible AEs by [CONTACT_249983][INVESTIGATOR_249960], and possible higher formulation-dependent fraction absorbed.
Peposertib has a nonclinical safety profile adequate for the treatment of patients with 
life-threatening advanced malignancies, and the safety profile does not raise concerns about further investigation of peposertib in participants with cancer. In addition, the available clinical safety datafor peposertib when given as a single agent forms a basis for the clinical study in combination with RT, as well as chemotherapy, and supports the investigation also in the neoadjuvant setting.
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N35/122In conclusion, emerging clinical safety data from studies EMR100036-001 and EMR100036-002, 
and supportive results of a comprehensive series of nonclinical safety pharmacology, PK, and toxicology studies, as well as primary and secondary PD findings support continued clinical 
development of peposertib in combination with RT, and/or chemotherapy.
3 Objectives and Endpoints
Study objectives and endpoints are provided in Table 6. Statistical analysis of the endpoints is 
described in Section 9.4.
Table 6 Study Objectives and Endpoints
Objectives Endpoints (Outcome Measures)Endpoints (Outcome Measures) 
Timeframe
Primary
To define an MTD and RP2D of 
peposertib in combination with capecitabine and RTOccurrence of dose limiting toxicities Time from first study intervention to 
the end of CRT with a final assessment at 4 weeks after surgery
Secondary
To evaluate safety and tolerability of peposertib in combination with capecitabine and RT!Occurrence of TEAEs and 
treatment-related adverse events according to the NCI-CTCAE version 5.0
!Occurrence of abnormalities 
(Grade≥3) in laboratory test 
values, markedly abnormal vital sign measurements, and clinically significantly abnormal ECGs 
including clinically important 
increases in QT interval (QTcF)Time from first study intervention to 
final assessment at 1 year
To explore antitumor activity of peposertib in combination with capecitabine and RT!Composite endpoint of pCR/cCR !Pathology evaluation of
specimen after surgery (pCR) and clinical evaluation 1 to 2 weeks prior to surgery 
(cCR)
!Disease-free Survival !Time from first study
intervention to final assessment at 1 year
!pCR !Pathology evaluation of
specimen after surgery
!cCR !Time from first study
Intervention until clinical evaluation 1 to 2 weeks prior to surgery
!Local recurrence and/or distant
metastasis!Time from surgery to final
assessment at 1 year
!Neoadjuvant rectal score !Pathology evaluation of 
specimen after surgery
To assess the PK of peposertib PK profile of peposertib in terms of
PK parameter estimates (e.g. C max, 
AUC 0-t, tmax, CL/f, Vz/f, t 1/2)FD1 and FD9
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N36/122cCR=Clinical Complete Response, CRT=chemoradiotherapy,  
 ECG=electrocardiogram, FD=fraction day, MTD=maximum tolerated dose, NCI-CTCAE=National Cancer 
Institute Common Terminology Criteria of Adverse Events, , pCR=Pathological Complete Response, PK=pharmacokinetic(s), RP2D=recommended Phase II dose, RT=radiotherapy, TEAE=treatment-emergent adverse event.
The definition of pathological complete response (pCR) and cCR, and derivation of the pCR/cCR 
composite endpoint are described in Section 3.1. Statistical aspects of other endpoints are 
described in Section 9.4.
3.[ADDRESS_303810] a pCR if they undergo surgery and no residual cancer is found 
on histological examination of the removed specimen (ypT 0N0).
The assessment of pCR will be based on local review of the histology slides.
CCI
CCICCI
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N37/122Clinical Complete Response
Participants are considered to have a cCR if all the criteria below are fulfilled:
!Absence of any residual tumor in the primary  site and draining lymph nodes on imaging with 
magnetic resonance imaging (MRI; T2weighted and diffusion weighted) as defined in the 
Appendix 5,  which is based on a modification of tumor evaluation as described by [CONTACT_249984] 2015 .
!No visible lesion at endoscopy except a flat scar, telangiectasia, and/or whitening of the mucosa
(documented by [CONTACT_249985])
!Absence of any palpable tumor or irregularity on digital rectal examination (DRE) and endoscopic ultrasonography (EUS) (if indicated or if performed)
!If a biopsy is taken, it must be negative.
Composite Endpoint of Pathological Complete Response/Clinical Complete Response
Participants are considered as responders to the composite endpoint pCR/cCR if 1 of the following 
2 criteria is fulfilled (Figure 2) :
!Participant had surgery and has pCR
!Participant did not undergo surgery but has cCR (defined above).
Participants who are not operated on and do not undergo the procedures to define cCR will be 
regarded as nonresponders.
Figure 2 Derivation of Composite Endpoint
cCR=Clinical Complete Response, CR=Complete Response, pCR=Pathological Complete Response, MRI=Magnetic 
Resonance Imaging. See Section  9.4for the statistical aspects of the endpoints.
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N38/[ADDRESS_303811] of a Screening period of 4 weeks, a Treatment period of 5 to 5.5 weeks (25 
or 28 fraction days [FDs]) (DLT period, see Section  6.6.1) , a Short-term Safety Follow-up period 
of 13.5 weeks including 30 days after surgery, a Long-term Safety Follow-up period until 1 yearafter the start of study intervention/randomization.
A schematic overview of the study is shown in Section 1.2. A detailed SoA is provided in 
Section 1.3.
4.1.[ADDRESS_303812] day of study intervention 
administration. Participants will be assessed for eligibility to participate in the study, and will undergo clinical evaluations to ensure compliance with the inclusion and exclusion criteria(Section 5.1and Section 5.2, respectively). Details of tumor evaluation methods at Screening are 
provided in Section 8.1.2.  Details of rescreening are provided in Section 5.4.For participants who 
received induction chemotherapy prior to the study , a DRE and endoscopy (and EUS if indicated 
or if performed per local practice) will need to be done  to determine current stage before starting 
CRT, in compliance with the inclusion criteria (Section 5.1).
4.1.[ADDRESS_303813] cohort will be 50 mg once daily (Section 4.3). 
Participants for next cohorts will be assigned to an peposertib dose determined by [CONTACT_4484]. The SMC dose recommendations will be guided by a Bayesian 2-parameter logistic regression model with overdose control (Appendix 10) . The planned cohort size is 3 participants. Peposertib will be 
given in combination with capecitabine at a dose of 825 mg/m
2twice daily and RT of 50 to 50.4 Gy 
to the tumor area and 45 Gy to the electively irradiated tissues in 25 or 28 fractions (corresponding to 5 to 5.5 weeks). Full details of the dosing regimens are provided in Section 6.6.2.
After each cohort has completed the 5 to 5.5-week treatment period (DLT period), the SMC will 
review safety, including DLT data, tolerability, and PK data if available, and will recommend the peposertib dose for the next cohort. In addition, any toxicities observed during the Short-term 
Safety Follow-up will be reviewed and considered by [CONTACT_249986]. Dose limiting toxicities are defined in Section 6.6.1. If the SMC decides to escalate the dose for the next cohort, it is in exceptional cases 
at discretion of the study team (medical lead and safety lead with input from statistician) to includeup to 3 further participants in parallel, on a dose level that has already been tested in a previouscohort.
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N39/122Participants will receive CRT until treatment completion after 25 or 28 RT fractions or disease 
progression, unacceptable toxicity or participant refusal to continue.
4.1.3 Follow-up Periods
The study follow-up will include:
!Short-term Safety Follow-up: the duration of the Short-term Safety Follow-up is 
approximately 13.5 to 14 weeks after treatment completion, including 30 days after surgery, 
with an optional 1 visit per week from Week 7 to Week 14 in case of acute toxicities until recovery to Grade 1 or to baseline. For all participants, a mandatory visit will be performed at Week 14, approximately 1 to 2 weeks prior to s urgery, including a tumor assessment with MRI
(T
2weighted and diffusion wei ghted) needed for restaging and evaluation. Additional details 
on tumor evaluation methods and response assessments are provided in Section 8.1.2.
!Surgical intervention must be performed 15 weeks (± 14 days) after start of study 
intervention/randomization (i.e. approximately 9.5 weeks after stoppi[INVESTIGATOR_249961]), unless there are contraindications for surgery, or if the participant refuses. The last Short-term Safety Follow-up visit is scheduled for Week 19, approximately 4 to 6 weeks after surgical intervention/imaging/biopsy, as per SoC. During this visit, all safety information since the last visit, including surgical and/or biopsy morbidities/toxicities will be collected.
!Long-term Safety Follow-up: participants will be followed-up at 21 and 27 weeks after start 
of study intervention/randomization; every 3 months until 1 year after start of study intervention/randomization. Details on tumor evaluation methods and response assessments are provided in Section 8.1.2.  Adjuvant chemotherapy is allowed as per local standards (see 
Section 6.5). Participants receiving adjuvant chemotherapy will continue to follow the schedule 
of activities (SoA) as per protocol. If adjuvant chemotherapy is given, any additional safety evaluations/laboratory tests will be as per local practice.
!Participants who have already been followed up for more than 1 year (Long-term Safety or Survival Follow-up) will be discontinued from  the study after the approval of protocol 
amendment version 4.0 by [CONTACT_249976]. Participants will be informed of the discontinuation by [CONTACT_249987] a phone call. No further study visits 
or assessments are planned.
4.2 Scientific Rationale for Study Design
Study Interventions:
!In this study, peposertib will be used in combination with capecitabine and RT. Peposertib is a potent and selective, ATP-competitive inhibitor of DNA-PK and blocks a major DSB repair pathway (nonhomologous end joining pathway). Inhibitors of DNA-PK are expected to 
synergistically enhance the therapeutic effect of DSB-inducing anticancer modalities.
!The current SoC for locally advanced rectal cancer is capecitabine, a prodrug of 5-fluorouracil(5FU), in combination with RT (NCCN 2019, Glynne-Jones 2017) . The mechanism of 5FU
cytotoxicity has been attributed to the mis-incorporation of fluoronucleotides into RNA and 
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N41/122as this study intervention is in the neoadjuvant setting and therefore potentially curative, the 
starting dose will be 50 mg to increase the probability that participants can complete the study intervention as per protocol.
Peposertib tablets will be given once daily and on RT days only. Peposertib has an apparent
terminal half-life (t
1/2) of approximately 5.5 h. Therefore, once daily dosing will give adequate 
exposure for the timeframe in which the DSB caused by [CONTACT_249988] (Kwok 1989,
Schulz 2017) .
Capecitabine will be administered at a twice daily dose of 825 mg/m2and RT will be given at a
total dose of 50 to 50.4 Gy to the tumor area and 45 Gy to the electively irradiated tissues in 25 or28 fractions. These doses are in accordance with current medical guidelines (NCCN 2019,Glynne-Jones 2017) .
See Section 6.6for dosing instructions and the procedures for selecting and modifying each 
participant’s dose.
4.4 End of Study Definition
A participant has completed the study if he/she has completed all study visits, interventions, and 
procedures, including the last schedu led activity shown in the SoA (Section 1.3). No further data 
will be collected from a participant after completion of the respective follow-up period (refer to Section 4.1.3) . 
The end of the study is defined as the date of the last scheduled activity, shown in the SoA 
(Section 1.3), for the last participant in the study globally.
The Sponsor reserves the right to close the study site or terminate the study at any time and for any 
reason (Appendix 2) .
5 Study Population
The criteria in Sections 5.1(Inclusion Criteria) and  5.2(Exclusion Criteria) are designed to enroll 
only participants who are appropriate for the study; thereby [CONTACT_249989]. All relevant medical and nonmedical conditions should be taken into consideration when deciding whether a participant is suitable for this study.
Prospective approval of protocol deviations to inclusion and exclusion criteria, also known as 
protocol waivers or exemptions, is not permitted.
Before performing any study assessments that are not part of the participant’s routine medical care, 
the Investigator will confirm that the participant or the participant’s legal representative (where allowed by [CONTACT_10976]) has provided written informed consent, as indicated in Appendix 2 (Study Governance).
Participants will be recruited based on referrals to study sites and local site review of participant 
profiles.
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N42/1225.1 Inclusion Criteria
Participants are eligible to be included in the study only if all the following criteria apply:
Age
1. Are ≥[ADDRESS_303814] an Eastern Cooperative Oncology Group Performance Status ≤[ADDRESS_303815] histologically confirmed and localized resectable rectal cancer (Stage II or Stage III at 
original staging). Participants who received induction chemotherapy are allowed to be enrolled to this study except if this induction is resulting in cCR or tumor progression (see Section 8.1.2 and Appendix 5) . Participants who received induction chemotherapy should be 
evaluated by [CONTACT_9268], endoscopy and DRE before start of study intervention/randomization (peposertib and CRT), see Appendix 5.  The following induction chemotherapi[INVESTIGATOR_249962]: FOLFOX (folic acid, 5-FU, and oxaliplatin) and CAPEOX (capecitabine and oxaliplatin) as per NCCN [ADDRESS_303816] adequate hematological function: hemoglobin ≥9 g/dL, neutrophils ≥1.5 × 10
9/L and 
platelets ≥100 × 109/L
7. Have adequate renal function: serum creatinine ≤1.5 × upper limit of normal (ULN) or 
creatinine clearance ≥50 mL/min (Cockcroft 1976)
8. Have adequate liver function: aspartate aminotransferase, alanine transaminase, alkaline 
phosphatase ≤3 × ULN, and bilirubin ≤1.5 × ULN
Sex
9. Are male or female
!Male participants:
Agree to the following during the study intervention period and for at least [ADDRESS_303817] dose of study intervention:
oRefrain from donating sperm
Plus, either: 
oAbstain from any activity that allows for exposure to ejaculate.
OR
oUse a male condom:
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N43/122When having sexual intercourse with a woman of childbearing potential, 
who is notcurrently pregnant, and advise her to use a highly effective 
contraceptive method with a failure rate of < 1% per year, as described in Appendix 3,  since a condom may break or leak.
When engaging in any activity that allows for exposure to ejaculate.
!Female Participants: 
oAre notpregnant or breastfeeding, and at least one of the following conditions 
applies:
Nota woman of childbearing potential
OR
If a woman of childbearing potential, use a highly effective contraceptive 
method (i.e. with a failure rate of < 1% pe r year), preferably with low user 
dependency, as described in  Appendix 3 for the following time periods:
oBefore the first dose of the study intervention(s), if using hormonal contraception:
Has completed at least one 4-week cycle of an oral contraception pi[INVESTIGATOR_249963]
Has used a depot contraceptive or extended-cycle oral contraceptive for 
least [ADDRESS_303818] using a highly sensitive assay.
AND
A barrier method, as described in  Appendix 3.
oDuring the intervention period
oAfter the study intervention period (i.e. af ter the last dose of study intervention is 
administered) for at least [ADDRESS_303819] dose of study intervention and agree not to donate eggs (ova, oocytes) for reproduction during this period.
The Investigator evaluates the effectiveness of the contraceptive method in 
relationship to the first dose of study intervention.
oHave a negative serum pregnancy test, as required by [CONTACT_427], within [ADDRESS_303820] dose of study intervention . Additional requirements for 
pregnancy testing during and after study intervention are in Section  8.2.4.
!The Investigator reviews the medical history, menstrual history, and recent sexual activity to 
decrease the risk for inclusion of a female with an early undetected pregnancy.
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N44/122Informed Consent
10. Can give signed informed consent, as indicated in  Appendix 2 (Study Governance), which 
includes compliance with the requirements and restrictions listed in an informed consent form (ICF) and this protocol.
Details of rescreening are provided in Section 5.4.
5.2 Exclusion Criteria
Participants are excluded from the study if any of the following criteria apply:
Medical Conditions
1. History of any other significant medical disease or psychiatric conditions that might in the 
assessment of the Investigator preclude safe participation in the study
2. History of difficulty swallowing, malabsorption, or other chronic gastrointestinal disease or 
conditions that may hamper compliance and/or absorption of the study intervention
3. Unstable cardiovascular function within 6 months prior to enrollment (i.e. ischemia,
symptomatic angina, congestive heart failure, Class III to IV New Y ork Heart Association
uncontrolled conduction abnormalities including a history of long QTc syndrome [QTcF > 480 ms] and/or pacemaker, or myocardial infarction)
4. Hypertension uncontrolled by [CONTACT_12617] (i.e. systolic blood pressure ≥150 mmHg and 
diastolic blood pressure ≥90 mmHg)
5. History of other malignant disease within th e past 5 years, other than successfully treated 
basal carcinoma of the skin or carcinoma in situ of the cervix
6. Known human immunodeficiency virus positivity, known active viral hepatitis, current 
alcohol abuse, or cirrhosis
7. Ongoing active infection or treatment with a live attenuated vaccine within 4 weeks of 
dosing.
Prior/Concomitant Therapy
8. Previous radiation therapy to the pelvis
9. Concurrent use of other anticancer therapy10. Major surgical intervention within [ADDRESS_303821] dose of study intervention. 
Biopsy(s) to establish the diagnosis for rectal cancer is permitted. Diverting ostomy is permitted
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N45/[ZIP_CODE]. Concomitant or prior use of medications or herbal supplements, known to be strong 
inhibitors of cytochrome P450 (CYP) 3A and/or CYP2C19, unless use can be discontinued [ADDRESS_303822] dose of study intervention. Concomitant or prior use of medications or herbal supplements, known to be strong inducers of CYP3A and/orCYP2C19, unless use can be discontinued at least [ADDRESS_303823] 1 day prior 
to receiving study intervention
12. Concomitant use of H
2-blocker or proton pump inhibitors (PPIs) (or unable to stop at least 
[ADDRESS_303824] treatment). Note that calcium carbonate is acceptable
13. Treatment with sorivudine or its chemically related analogues, such as brivudine
Prior/Concurrent Clinical Study Experience
14. Participation in any interventional clinical study within 28 days prior to Screening or during 
participation in this study
Diagnostic Assessments
15. Contraindications to MRI imaging
Other Exclusions
16. Pregnant or nursing (lactating) women
17. Known dihy dropyrimidin e dehydrogenase deficiency
18. History of severe and unexpected reactions to fluoropyrimidine therapy19. Hypersensitivity to capecitabine or to any of the excipi[INVESTIGATOR_249964].
5.3 Lifestyle Considerations
5.3.1 Meals and Dietary Restrictions
The timing of meals relative to dosing of study interventions and fasting requirements are detailed 
in the SoA (Section 1.3)and Section 6.6.2.
Participants will be instructed to refrain from consumption of red wine, Seville oranges, grapefruit 
or grapefruit juice, Seville orange marmalade, star fruit, or other products containing grapefruit, Seville oranges or star fruit from [ADDRESS_303825] alcohol, or tobacco use apply during this study, with the exception of red wine (Section 5.3.1) .
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N46/1225.3.3 Activity
Electrocardiograms (ECG) will be obtained after the participant has been in a semi-supi[INVESTIGATOR_49844] 5 min (Section 8.2.3) .
Participants will abstain from strenuous exercise for 2 h before each blood collection for clinical 
laboratory tests. Participants may participate in light recreational activities.
5.4 Screen Failures
Individuals who do not meet the criteria for particip ation in this study (potential participants who 
failed screening) may be rescreened. Rescreened participants will be assigned a new participant number. Retesting before baseline will be permitted only once, and the test for the specific abnormal value must be repeated within the time frame of the Screening period. The last value of 
the previously questioned test result must meet the study criteria before start of study intervention.In the case of a rescreen and the screening CT scan is > [ADDRESS_303826] be repeated.
6 Study Intervention(s)
Study intervention is any investigational intervention(s), marketed product(s), placebo, or medical device(s) intended to be administered to a study participant per the study protocol. For this study, peposertib is the investigational intervention, and the study interventions include peposertib, capecitabine, and RT. Peposertib and capecitabine will be administered on an outpatient basis, except on dosing days requiring predose PK samples (Table 4, Table 7) .
6.1 Study Intervention(s) Administration
Study interventions are summarized in  Table 7.
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N47/122Table 7 Description of Study Interventions
Study Intervention 
Name: [CONTACT_250018]: Film-coated tablet Film-coated tablet
Unit Dose Strengths: 50 mg 150 mg/500 mg
Route of Administration: Oral Oral
Dosing Instructions: Administered at home (except on days 
requiring predose PK sample), once daily 
and on RT days only. Take [ADDRESS_303827] peposertib intake. 
On days when predose PK sample is 
drawn (Fraction Days 1, 2, 9, and 10), 
dose should be taken at the clinic after 
the predose PK blood draw.
See Section 6.6for dose selectionAdministered at home (except for the 
morning dose on days requiring 
predose PK sample) and on RT days 
only. Take within 30 min after meal 
(breakfast/dinner). On days when 
predose PK sample is drawn (Fraction 
Days 1, 2, 9, and 10), morning dose 
should be taken at the clinic after the 
predose PK blood draw.
See Section 6.6for dose selection
Packaging and Labeling Study intervention will be provided in 
aluminum/aluminum blisters.
Each blister will be packaged and labeled 
per all applicable regulatory requirements 
and Good Manufacturing Practice 
GuidelinesStudy intervention will be provided as a 
marketed product. It will be prepared in 
accordance with its product labeling
PK=pharmacokinetics, RT=radiotherapy.
!Capecitabine is administered as part of the study. General guidance on the use of capecitabine 
is provided. However, Investigators must follow and instruct participants to follow the package 
insert, the Product Information, the Summary of Product Characteristics (SmPC), and their site’s specific policies/instructions for the final use of capecitabine.
6.2 Study Intervention(s) Preparation, Handling, Storage, and 
Accountability
!Peposertib will be supplied as formulated film-coated tablets intended for ready-to-use oral 
administration. The aluminum ‘ALU/ALU’ blisters are used as the container closure system for peposertib film-coated tablets.  
!The preparation, handling and storage of capecitabine at the study site will be in accordance with its product label. Investigators or assigned staff should instruct participants on proper handling and storage.
The Investigator, institution, or the head of the medical institution (where applicable) is responsible 
for study intervention accountability, reconciliation, and record maintenance (i.e. receipt, reconciliation, and final disposition records).
CCI
CCICCICCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N48/122After completion of the study, any study intervention distributed to the site but not administered, 
dispensed to or taken by [CONTACT_249990]. Details will be agreed upon between the Sponsor and the Investigator. All unused  medications will be carefully recorded and 
documented before destruction. The Investigator will ensure the supplied study intervention is not used for any purpose other than this study.
!Upon receipt of the study intervention(s), the Investigator or designee must confirm appropriate temperature conditions have been maintained during transit and any discrepancies are reported and resolved before use. Also, the responsible person will check for accurate delivery and acknowledge receipt by [CONTACT_249991]. A copy will be archived for the Investigator Site File.
!Any temperature excursion during shipment or damaged receipt must be properly documented in the Interactive Voice/Web Response System (IVRS/IWRS) and the sending site must be informed.
!Only participants enrolled in the study may receive study intervention(s) and only authorized 
site staff may supply it. All study intervention(s) must be stored in a secure, environmentally-controlled, and monitored (manua l or automated) area, in accordance with the 
labeled storage conditions, and with access limited to the Investigator and authorized site staff.
!Dispensing will be recorded on the appropriate accountability forms so that accurate records will be available for verification at each monitoring visit.
!Each study site must ensure that the study intervention(s) is not used:
oAfter the expi[INVESTIGATOR_5695], or
oAfter the retest date unless the study intervention is reanalyzed and its release date 
extended.
This is to be closely monitored by [CONTACT_11200].
!Study intervention(s) accountability records at the study site will include the following:
oConfirmation of receipt, in good condition and in the defined temperature range.
oThe inventory provided for the clinical study and prepared at the site.
oThe dose(s) each participant used during the study.
oThe disposition (including return, if applicable) of any unused study 
intervention(s).
oDates, quantities, batch numbers, kit numbers, expi[INVESTIGATOR_4061]/use-by [CONTACT_57583], and the 
participant numbers.
!The Investigator site will maintain records, which adequately documents that participants were provided the doses specified in this protocol, a nd all study intervention(s) provided were fully 
reconciled.
!Unused study intervention(s) must not be discarded or used for any purpose other than the present study. No study intervention that is dispensed to a participant may be redispensed to a different participant.
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N49/122!A Study Monitor will periodically collect the study intervention(s) accountability forms.
!Further guidance and information for the final disposition of unused study intervention(s) are 
provided in the Clinical Operations Plan.
6.3 Measures to Minimize Bias: Study Intervention Assignment 
and Blinding
6.3.1 Study Intervention Assignment
!The IVRS/IWRS will be used to assign unique participant numbers, and study intervention to 
participants at each study intervention visit.
!Before the study is initiated, the telephone number and call-in directions for the IVRS and/or the log-in information and directions for the IWRS will be provided to each site. The site will contact [CONTACT_21926]/IWRS prior to starting study intervention administration for each participant. The site will record the study intervention assignment in the applicable Case Report Form (CRF).
6.3.2 Blinding
Blinding is not applicable as this is an open-label study.
6.4 Study Intervention Compliance
!Acceptable compliance for this study will be defined in the Monitoring Plan.
!Measures to monitor and document participants’ compliance with study intervention will include: 
oPatient diaries used to document the dates and times of study intervention 
administration and to support the participant in planning the correct times to take study intervention(s)
oCompliance will be captured in the source documents using electronic data capture,
reviewed by [CONTACT_249992].
!Participants must be withdrawn from the study intervention in the event of noncompliance that is deemed by [CONTACT_249993] (Section 7.1and Section 8.4).
!The following procedures will be used for increasing compliance:
oUse of patient diaries
oRegular review of dosing with the participant.
Further details of procedures used for increasing compliance will be included in the Monitoring 
Plan.
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N50/1226.5 Concomitant Therapy
!Adjuvant chemotherapy is allowed during the Long-term Safety Follow-up period if initiated 
within 1 to 3 months after surgery. The following adjuvant chemotherapi[INVESTIGATOR_33938]: FOLFOX and CAPEOX or capecitabine as per NCCN 2019 guidance.
!Drugs mainly metabolized by [CONTACT_097]3A with a narrow therapeutic index are to be used with 
caution. Examples of drugs are found on the following page: 
https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm. The Investigator may decide not to include a participant in the study, if the participant cannot withdraw the drugs that have a narrow therapeutic index and that are known to be metabolized via CYP3A; if the Investigator decides to enroll a participant who is treated with one of these drugs, close safety monitoring is advised.
!Record in the electronic Case Report Form (e CRF) all concomitant therapi[INVESTIGATOR_014] (e.g. medicines or 
nondrug interventions) used from the time the participant signs the informed consent until completion of the study, including any changes. For prescription and over-the-counter medicines, record the name, reason for use, dates administered, and dosing information.
Contact [CONTACT_108086].
6.5.1 Prohibited Medicines
!Participants must not have received any prior anticancer therapy for locally advanced rectal 
cancer including experimental agents, except induction chemotherapy. Use of any investigational agent within [ADDRESS_303828] study intervention administration is prohibited.
!During the treatment period and up to [ADDRESS_303829] study intervention administration, any 
other investigational agent, or any other anticancer therapy (i.e. chemotherapy, RT, biologics,
other targeted therapy, or immunotherapi[INVESTIGATOR_014]) are prohibited. Use of any investigational agent during the entire study duration is not permitted.
!Medications or herbal supplements known to be strong inhibitors or inducers of CYP3A or CYP2C19, are prohibited. A list is provided on the following page: https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm, although this list may not be exhaustive.
!The solubility of peposertib is pH dependent; therefore, antacid drugs, H 2-blocker and PPIs 
might affect absorption. PPIs should be stopped [ADDRESS_303830] 4 h before the evening dose of capecitabine and 8 h before peposertib dose in the next morning.
!Capecitabine must not be administered concomitantly with sorivudine or its chemically related analogues, such as brivudine. Concomitant use of allopurinol with capecitabine should be avoided. Caution is required with concomitant use of leucovorin with capecitabine as per standard practice.
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N51/122If prohibited concomitant therapy becomes necessary during the treatment period, e.g. due to AEs, 
the participant should be interrupted for a safe duration of time.
6.6 Dose Selection and Modification
Physician discretion may be used if monitoring or dose modification outside of the guidelines is considered necessary.
If participants vomit after taking their dose of peposertib and/or capecitabine, they should be given 
an antiemetic but the dose(s) will not be replaced. Prophylactic antiemetics should then be considered prior to subsequent doses of peposertib and/or capecitabine. Any change from dosing schedule, dose interruptions, or dose reductions should be recorded in the eCRF.
In general, each participant will stay on the pe posertib, and capecitabine dose level assigned in the 
study unless treatment needs to be interrupted, modified or stopped. If peposertib dosing interruptions are necessary, the SMC may decide to start the next cohort at a lower dose level or at a lower dosing intensity (e.g. three times weekly or twice weekly).
If [ADDRESS_303831] be withheld, that study intervention’s dose should be skipped rather 
than delayed, and the other study intervention (capecitabine or peposertib) should be given alone.
If hemoglobin is < 8 g/dL then appropriate measures according to standard clinical practice must 
be taken prior to any further dose administration.
The SMC will be responsible for dose escalation decisions and will provide input into the selection 
of a RP2D. Details of SMC decision making processes are provided in Appendix 2.  The DLT 
definition is provided in Section 6.6.1.
6.6.1 Definition of Dose Limiting Toxicity
A DLT is defined as any of the following TEAEs considered possibly related to peposertib and/or 
capecitabine and/or RT by [CONTACT_11219]/or the Sponsor up to completion of the assigned 
CRT treatment (25 FD or 28 FD) (DLT period). A DLT must be confirmed by [CONTACT_4484]:
1. An adverse drug reaction that, in the opi[INVESTIGATOR_249965], is of potential clinical 
significance such that further dose escalation would expose participants to unacceptable risk
2. Any occurrence of drug-induced liver injury (DILI) meeting the Hy’s law criteria (i.e.
defined as aminotransferases > 3 × ULN, alkaline phosphatase < 2 × ULN, total bilirubin ≥2 × ULN, with no other reason to account for these abnormalities)
3. Any Grade 3 toxicity, excluding:
a) Diarrhea (< 7 days duration) despi[INVESTIGATOR_249966], adequate and optimal antidiarrhea 
therapy
b) Neutropenia lasting for ≤5 days and not associated with fever
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N52/122c) Isolated Grade 3 lymphocytopenia without clinical correlate
d) Grade 3 radiation dermatitis that resolves to Grade ≤2 with supportive measures 
within 5 weeks
e) Nausea and vomiting (< 3 days duration) with adequate and optimal therapyf) Fatigue or headache (< 7 days duration) following initiation of adequate supportive 
care
g) Any other single laboratory values out of the normal range that have no clinical 
significance as confirmed by [CONTACT_737], and that resolve to Grade 2 or less with adequate measures within 7 days
h) Grade 3 thrombocytopenia without bleeding
4. All Grade ≥[ADDRESS_303832] possibly related to study intervention, irrespective of duration, 
excluding:
a) Isolated Grade 4 lymphocytopenia without clinical symptomsb) Neutropenia lasting for ≤5 days and not associated with fever
5. Any toxicity related to study intervention th at causes the participant to receive less than 
80% of the planned peposertib, capecitabine or RT dose
6.6.2 Dosing Instructions
See Table 7.
[IP_ADDRESS] Peposertib
The participants will take peposertib orally once daily in the morning for 5 days a week (on all 
FDs) throughout the RT course in combination with capecitabine (Figure 3) .
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N54/122    (  )=     ℎ  (  )×    ℎ  (   )
[ADDRESS_303833] 10% from baseline, the individual capecitabine doses 
should be recalculated. Otherwis e the initial body s urface area should be utilized for subsequent 
doses.
Capecitabine will be administered orally at a dose of 825 mg/m2twice daily 5 days a week 
throughout the RT course. The total daily dose, calculated in terms of mg/m2, will be rounded to 
the nearest 500 mg, to allow for tablet size, and then divided into 2 doses. If this results in an 
uneven number of tablets (e.g. 7 tablets daily), then then the larger number will be taken with the 
morning dose (i.e. 4 tablets in the morning and 3 tablets in the evening). Capecitabine tablets are not to be split.
In addition, participants will be instructed to:
!Take capecitabine tablets in 2 daily doses: a morning dose and an evening dose
!Swallow capecitabine tablets with water within 30 min after a meal (breakfast and dinner).
[IP_ADDRESS] Radiotherapy
Radiotherapy will be given at a total dose of [ADDRESS_303834] is allowed based on local guidelines (NCCN 2019, Glynne-Jones 2017) . Radiotherapy will be given [ADDRESS_303835] for dose planning and rigorous constraints for organs at risk (OAR).Participants must be treated with fields that at least include the tumor, presacral nodes, mesorectal region, and internal iliac nodes. In addition, quality assurance on the delivered dose and fields will be mandated. Details are provided in  Appendix 4.
[IP_ADDRESS] Administration of the Combination Therapy
The regimen for the study consists of once daily administration of peposertib together with 
capecitabine and RT:
!Capecitabine should be given within 30 min after  a meal in 2 daily doses (a morning dose and 
an evening dose)
!Peposertib should be given 1 h after a meal
!Radiotherapy should be given 1.5 h (± 30 min) after peposertib dosing.
The combination therapy follows the SoC therapy schedule, which is generally administered over 
25 or 28 FDs.
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N55/1226.6.[ADDRESS_303836] weekly  during CRT when acute t oxicity assessments are 
performed. 
The following guidance should be followed for the management of acute toxicity and dose 
modifications:
!AEs should be graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0)
!In the event of overlappi[INVESTIGATOR_50685], dose modification should be based on the worst toxicity grade observed.
!All dose modifications should be documented with clear reasoning and documentation of the approach taken in the case report and in the medical notes.
!If a participant experiences a toxicity, then dose modifications should be applied as per protocol, 
even if the toxicity has resolved by [CONTACT_249994].
[IP_ADDRESS] Diarrhea
It is particularly important to assess and monitor participants who experience diarrhea during CRT. Recommendation for participants who experience diarrhea during concurrent CRT is given in the diarrhea management charter. 
[IP_ADDRESS] Capecitabine Management for Toxicities Other Than 
Diarrhea
Investigators must follow the package insert, the product information, the SmPC, and their site’s 
specific policies/instructions for the final use of capecitabine.
Toxicity due to capecitabine administration may be managed by [CONTACT_230817]/or 
modification of the dose (treatment interruption or dose reduction). Once the dose has been reduced, it should not be increased at a later time. For those toxicities considered by [CONTACT_249995]-threatening, e.g. alopecia, altered taste, nail changes, treatment can be continued at the same dose without reduction or interruption. Participants taking capecitabine should be informed of the need to interrupt treatment immediately if moderate or severe toxicity occurs. Doses of capecitabine omitted for toxicity will not be
replaced.
Hematological Toxicity
Participants with baseline neutrophil counts of < 1.5 × 10
9/L and/or platelet counts of 
< 100 × 109/L should not be treated with capecitabine. If these counts drop during treatment, doses 
of capecitabine are modified as shown in Table 8.
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N56/122Table 8 Dose Adjustment for Capecitabine for Absolute Neutrophil Count 
and/or Platelet Counts
Cell Count Order of 
OccurrenceAction Dose Resumed at (% 
of Starting Dose)
ANC≥1.0 × 109/L and platelets
≥75 × 109/LMaintain capecitabine dose 100%
ANC < 1.0 × 109/L and/or 
platelets < 75 × 109/LFirst occurrence Interrupt treatment until 
ANC≥1.0 × 109/L and platelets
≥75 × 109/L100%
ANC < 1.0 × 109/L and/or 
platelets< 75 × 109/LSecond 
occurrenceInterrupt treatment until 
ANC≥1.0 × 109/L and platelets
≥75 × 109/L75%
ANC < 1.0 × 109/L and/or 
platelets < 75 × 109/LThird 
occurrenceInterrupt treatment until 
ANC≥1.0 × 109/L and platelets
≥75 × 109/L50%
ANC < 1.0 × 109/L and/or 
platelets < 75 × 109/LFourth 
occurrenceDiscontinue capecitabine 
treatmentNot applicable
ANC=absolute neutrophil count.
Nonhematological Toxicity
For nonhematological toxicity due to capecitabine, doses are to be modified in line with  Table 9.
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N57/122Table 9 Dose Adjustment for Capecitabine According to Common Terminology 
Criteria of Adverse Events Version 5.0 – Nonhematological Toxicity
Order of 
OccurrenceGrade [ADDRESS_303837] 
OccurrenceInterrupt treatment until 
resolved to Grade 0/1, then 
continue at 100% or original 
capecitabine doseInterrupt treatment until 
resolved to Grade 0/1, then 
continue at 75% or original 
capecitabine doseDiscontinue capecitabine 
treatment
Second OccurrenceInterrupt treatment until 
resolved to Grade 0/1, then 
continue at 75% or original 
capecitabine doseInterrupt treatment until 
resolved to Grade 0/1, then 
continue at 50% or original 
capecitabine dose
Third OccurrenceInterrupt treatment until 
resolved to Grade 0/1, then 
continue at 50% or original 
capecitabine doseDiscontinue capecitabine 
treatment
Fourth OccurrenceDiscontinue capecitabine 
treatment
Source: EU Summary of Product Characteristics Version 02 February 2006.
[IP_ADDRESS] Peposertib and Radiotherapy
The criteria for peposertib and RT dose modification in the study are included in Table 10.
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N58/122Table 10 Dose Modifications of Peposertib and Radiotherapy During the Study
for toxicities other than Diarrhea
Dose Modifications
Toxicity PeposertibaRadiotherapyb
Toxicities in Radiation Field Grade 4
!Radiation dermatitis. Temporarily interrupt peposertib. 
Resume treatment once severity resolves to Grade ≤3. Maximum delay 
of up to and including 7 days; otherwise permanently discontinue study 
intervention.Temporarily interrupt 
treatment. Resume treatment once severity resolves to Grade ≤3
and dose distribution 
may be adjusted to 
spare skin.
Systemic Toxicities
Hematologic Toxicities:
Any Grade ≥3 toxicity, excluding:
!Neutropenia lasting for ≤5 days and not 
associated with fever
!Isolated Grade 4 lymphocytopenia 
without clinical correlate
!Grade 3 thrombocytopenia without 
bleeding.Temporarily interrupt peposertib. 
Resume treatment (at the same dose) once severity resolves to Grade ≤1 or 
baseline. Maximum delay of 7 days; otherwise permanently discontinue 
peposertib. If there is a second 
recurrence at the same grade, permanently discontinue peposertib.No action to be taken.
Nonhematologic Toxicities:
Any Grade ≥3 toxicity, excluding:
!Nausea and vomiting (< 3 days 
duration) with adequate and optimal 
therapy
!Fatigue or headache (< 7 days duration) 
following initiation of adequate supportive care
!Any other single laboratory values out of 
the normal range that have no clinical 
significance, and that resolve to Grade≤2 with adequate measures 
within 7 days.Temporarily interrupt peposertib. 
Resume treatment (at the same dose) once severity resolves to Grade ≤1 or 
baseline. Maximum delay of 7 days; 
otherwise permanently discontinue 
study intervention. If there is a second recurrence, permanently discontinue peposertib.
If Grade ≥[ADDRESS_303838] 
every 4 days until recovery to 
Grade≤2.No action to be taken.
Treatment-related hepatocellular damage 
for more than 3 days, such as Grade≥[ADDRESS_303839] with or without 
elevation of serum total bilirubin to 
> 2 × ULN, without initial findings of cholestasis (elevated serum alkaline phosphatase) or other apparent clinical 
causality.
ALT=alanine aminotransferase, AST=aspartate aminotransferase, ULN=upper limit of normal.
a As all treatments with peposertib will be given in combination with radiotherapy, an interruption in the 
administration of radiotherapy would lead to an interruption in treatment with peposertib.
b A maximum radiotherapy delay of up to and including [ADDRESS_303840] be 
discontinued from peposertib.
Severity of adverse events will be graded using the Common Terminology Criteria for Adverse Events (version 5.0) 
toxicity grades.
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N59/1226.6.3.4 Radiotherapy Treatment Delay
Within this study, a maximum delay of up to a nd including 7 days in total is allowed within the 
complete Treatment period (Table 10) . If RT and study intervention must be delayed by [CONTACT_726] 
[ADDRESS_303841] be permanently discontinued from study intervention.
As all treatments with peposertib will be given in combination with RT, an interruption in the 
administration of RT would lead to an interruption in treatment with peposertib. Capecitabine can 
be continued or discontinued according to local guidelines.
If a participant misses RT administration, then the missed RT day will be made up (i.e. the missed 
RT dose is not skipped); participants should receive a total of 25 or 28 RT fractions.
6.7 Study Intervention After the End of the Study
After a participant has completed the study or has withdrawn prematurely, usual treatment will be administered, if required, in accordance with the study site’s SoC and generally accepted medical practice and depending on the participant’s individual medical needs.
6.8 Special Precautions
!Participants should be carefully monitored for ophthalmological complications such as keratitis and corneal disorders according to local guidelines.
!Caution should be exercised with the intake of anticoagulants, phenytoin and/or leucovorin, and of drugs mainly metabolized by [CONTACT_097]3A with a narrow therapeutic index.
!Care should be exercised when capecitabine is coadministered with CYP2C9 substrates, e.g.phenytoin. Participants taking phenytoin concomitantly with capecitabine should be regularly monitored for increased phenytoin plasma concentrations.
!Participants taking coumarin-derivative anticoagulants concomitantly with capecitabine should be monitored regularly for alterations in their coagulation parameters (prothrombin time or international normalized ratio) and the anticoagulant dose adjusted accordingly.
!Capecitabine dosing should be discontinued in the event of severe mucocutaneous reactions. Capecitabine dosing should be interrupted in the event of hand-and-foot syndrome, hyperbilirubinemia, and low neutrophil or platelet counts.
Further details of special precautions for capecitabine are available in the Product 
Information/SmPC.
See Section 5.3.[ADDRESS_303842] of the study will be closely monitored and specific instructions for monitoring and management of expected toxicities will be incorporated into the protocol and the Investigator’s 
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N60/122Brochure. When further safety data for this study intervention combination become available, risk 
assessment and mitigation activities will be reviewed to assess the continued appropriateness.
The management of toxicity due to capecitabine administration is described in Section [IP_ADDRESS].
Toxicities related to RT will be managed according to the local institute’s guidelines.
7 Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal
7.[ADDRESS_303843] be withdrawn from the study intervention in the event of any of the following:
!Therapeutic failure requiring urgent additional medication, such as administration of new 
anticancer therapy that is considered more suitable according to the Principal Investigator
!Discontinuation of RT if participant is unable to tolerate < 80% of the planned RT dose
!Adverse events that cause RT delays of > 7 days
!Occurrence of AEs, if discontinuation of study in tervention is desired or considered necessary 
by [CONTACT_737], or if after temporary treatment interruption the AE does not resolve or worsens in severity
!Pregnancy of participant
!Prohibited concomitant therapy (as defined in Section 6.5.1)  where the predefined consequence 
is withdrawal from the study intervention
!Noncompliance that is deemed by [CONTACT_249996].
The SoA (Section 1.3) specifies the data to collect at study intervention discontinuation and 
follow-up, and any additional evaluations that need  to be completed. Participants who discontinue 
study intervention must be followed on study including completion of study assessments, including 
at minimum tumor assessments until disease progression, until resolution of toxicity or discontinuation from study.
7.1.1 Temporary Discontinuation
Formal criteria for the dose modification, including temporary interruption where applicable, for capecitabine are provided in Section [IP_ADDRESS],  and for peposertib and RT are provided in 
Section [IP_ADDRESS].
7.1.2 Rechallenge
Not applicable.
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N61/1227.2 Participant Discontinuation/Withdrawal from the Study
!A participant may withdraw from the study at any time, at his/her own request or may be 
withdrawn at any time at the discretion of the Investigator for safety, behavioral, compliance, or administrative reasons.
!At the time of discontinuing from the study, if possible, a discontinuation visit will be 
conducted, as listed in the SoA. The SoA specifies the data to collect at study discontinuation 
and follow-up, and any additional evaluations that need to be completed.
!If the participant withdraws consent for future involvement in the study, any data collected up to that point may still be used, but no future data can be generated, and any biological samples collected will be destroyed.
!A participant has the right at any time to request destruction of any biological samples taken. The Investigator must document this in the site study records.
Participants should be explicitly asked at time of discontinuation of study if they would allow 
survival information to be collected including veri fication of medical/public records as permitted 
by [CONTACT_427]. These responses should accordingly be captured in the participant’s source data and reported in the eCRF accordingly.
The SoA (Section 1.3) specifies the data to collect at study discontinuation and follow-up, and any 
additional evaluations that need to be completed.
Participants who are discontinued/withdrawn from the study will not be replaced.
7.[ADDRESS_303844] be taken if a participant fails to return to the clinic for a required study 
visit:
!The site must attempt to contact [CONTACT_185610], counsel the participant on the importance of maintaining the assigned visit schedule, and ascertain if the participant wants to or should continue in the study.
!Before a participant is deemed “lost to follow-up”, the Investigator or designee must make every effort to regain contact [CONTACT_6635]: 1) where possible, make 3 telephone calls; 2) if necessary, send a certified letter (or an equivalent local method) to the participant’s last known mailing address, and 3) if a participant has given the appropriate consent, contact [CONTACT_2299]’s general practitioner for information. These contact [CONTACT_13140]’s medical record.
!Should the participant continue to be unreachable, he/she will be considered to have withdrawn from the study.
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N62/1228 Study Assessments and Procedures
!Study assessments and procedures and their timing are summarized in the SoA (Section 1.3).
!Noprotocol waivers or exemptions are allowed.
!Immediate safety concerns should be discussed with the Sponsor immediately upon occurrence 
or awareness to determine if the participant should continue or discontinue study intervention.
!Adherence to the study design requirements, including those specified in the SoA (Section 1.3), 
is essential and required for study conduct.
!All Screening evaluations must be completed  and reviewed to confirm that potential 
participants meet all eligibility criteria. The Investigator will maintain a screening log to record details of all participants screened, to confirm eligibility, and if applicable, record reasons for screening failure.
!Prior to performing any study assessments that are not part of the participant’s routine medical care, the Investigator will obtain written informed consent as specified in Appendix 2 (Study 
Governance).
!Procedures conducted as part of the participant’s routine medical care (e.g. blood count) and obtained before signing of the ICF may be used for Screening or baseline purposes provided the procedures met the protocol-specified criteria and were performed within the time frame defined in the SoA (Section 1.3).
!Regarding the visits from Week 7 to 14 during the short-term safety follow-up (Table 1) .T h e  
Week 14 visit is mandatory as this is needed for re staging and evaluation. All other visits in this 
period are optional and needed only in case of acute toxicities until recovery to Grade 1 or baseline.
!A maximum of 255 mL of blood will be collected in any one-month period from each participant in the study, including any extra assessments that may be required.
Screening:
Participants will be screened between Days -[ADDRESS_303845] dosing on Day 1. Assessments 
and procedures to be performed at Screening are detailed in the SoA (Section 1.3). 
Screening-specific procedures include:
!Demography: date of birth, sex (gender), race, and ethnicity.
!Medical history: disease history, previous illness and surgeries (e.g. all during the past year 
and only major ones prior to that), concomitant illness, relevant medication, allergies, therapi[INVESTIGATOR_249967], tobacco use including pack years, and alcohol use.
!Eastern Cooperative Oncology Group Performance Status: assessed at Screening to assess 
eligibility (Section 5.1) and then assessed according to the SoA (Section 1.3).
!Chest-abdominal computerized tomography (CT): A CT scan of the chest and abdomen will 
be performed prior to the beginning of study intervention to document the baseline status of the participant. Computerized tomography will be performed with intravenous iodinated contrast unless contraindicated. Evaluation up to 28 days prior to start of study intervention is allowed.
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N63/122In the case of a rescreen and the screening CT scan is > [ADDRESS_303846] will need to be repeated.
!DRE and endoscopy (and EUS if indicated or if performed): for participants who have 
received induction chemotherapy prior to start of study
Surgery
Participants will undergo surgery using TME 15 w eeks (± 14 days) after start of RT according to 
a standardized technique, unless there are contraindications for surgery (Ridgway 2003,  
Parfitt 2007) , if the participant refuses, or if the participant has a cCR and is eligible for organ 
preservation.
The choice of the surgical procedure, abdominoperineal resection or low anterior resection, is at 
the surgeon’s discretion. Further details will be described in a dedicated surgical charter.
8.[ADDRESS_303847] be 
submitted. 
The American Joint Committee on Cancer (AJCC) 8th edition (Amin 2017) will be used to 
categorize the completeness of the TME resection.
Reports must contain information about microscopic involvement and surgical resection margins.
If there is residual macroscopic tumor, standard pathological examination will be carried out with [ADDRESS_303848] procedures and the circumferential resection margin (CRM) will be measured (Washington 2009) . The status of the surgical CRM will be defined as involved if there 
is tumor within 1 mm of the CRM.
The extent of residual tumor in the resected specimen will be classified according to the Tumor 
Node Metastases staging system of the 8th edition AJCC, with the prescript “y” to indicate that the tumor had been treated before surgical resection. After preoperative CRT, residual tumor masses will be semi-quantitatively evaluated according to the 4-point regression grading scale Modified Ryan scheme for tumor regression score (see  Appendix 6) .
A pCR will be defined as the absence of viable tumor cells in the primary tumor and lymph nodes 
(ypT0N0).
Standard data on pathology, completeness of resection, and the response to neoadjuvant 
chemotherapy will be collected. The slides will be locally reviewed to record whether there was 
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N64/122macroscopic clearance of the tumor. Assessments of the pathology must be according to 
international guidelines and will be further described in  Appendix 6.
8.1.[ADDRESS_303849] of MRI only. For all participants the assessments after chemoradiation (Week 14) will include MRI, endoscopy and DRE and biopsy, if required. This is all based on a modification of tumor evaluation as described by  [CONTACT_249984] 2015. Tumor assessments done during long-term Safety Follow-up will only 
include MRI ( T
2weighted and diffusion weighted) or CT scans (Table 1 andTable 2) .
Baseline assessments are to be taken not earlier than 4 weeks prior to study intervention 
start/randomization. After study intervention start/randomization, tumor assessments will be performed at 14 weeks (± 7 days) after study intervention start/randomization (i.e. before surgery) and 27 weeks (± 2 week) after study intervention start/randomization, every 3 months thereafter (± 2 weeks) until 1 year after study intervention start/randomization.
[IP_ADDRESS] Evaluation Methods
MRI: A standard and diffusion-weighted MRI sequen ces will be obtained in 1.5T or 3T units by 
[CONTACT_2329] a phased array body coil. All images will be interpreted by [CONTACT_249997], clinical staging, according to standard clinical criteria, including extramural vascular invasion and CRM assessment. For all participants, evaluation up to 28 days prior to start study intervention/randomization is allowed.
If induction chemotherapy was given, an MRI must be done to evaluate tumor changes after 
chemotherapy. It should be done as described above and within [ADDRESS_303850] day of chemotherapy but before starting study intervention/randomization.
Endoscopy with photography: Is to be done along with DRE and MRI. The length of the tumor 
is defined as the difference between the distance of the proximal and distal margins of the lesion in relation to the anal verge. 
If participant received induction chemotherapy, endoscopy will be performed 2 weeks (± 14 days) 
after the last day of chemotherapy but before starting study intervention/randomization to evaluate tumor changes after chemotherapy.
Digital Rectal Exam: If the tumor cannot be reached on digital rectal exam, this should be noted 
on the checklist and evaluation. The digital rectal exam criteria are applicable to participants with palpable tumor only. 
In case induction chemotherapy was given, a DRE must be done to evaluate tumor changes after 
chemotherapy. It should be done within 2 weeks (± 14 days) after the last day of chemotherapy but before starting study intervention/randomization.
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N65/122Biopsy: Only to be done during the endoscopy if required and as per institutional guidelines.
[IP_ADDRESS] Tumor Response Evaluation
After induction chemotherapy : Response evaluation after induction chemotherapy and restaging 
before study intervention with peposertib and CRT are provided in Appendix 5.  The evaluation 
with MRI, endoscopy, and DRE is to be done before starting treatment/randomization (peposertib 
and CRT). Overall response is evaluated as progressive disease, stable disease, partial response, 
nearly complete response, or complete response. Participants who present with stable disease, partial response, or nearly complete response may enter the study, participants who present with tumor progression or cCR should be treated according to standard practice per institutional guidelines.
After peposertib and CRT: Response evaluation criteria after treatment and restaging before 
surgery are provided in  Appendix 5.  The evaluation with MRI, endoscopy, and DRE is to be done 
at Week 14 (± 7 days). Overall response is evaluated as progressive disease, incomplete response, nearly complete response, or complete response.
During Long-term Safety Follow-up: Response evaluation is provided in  Appendix 5.  
If a scan shows progressive disease, it will be indicated whether it is local recurrence, distant 
recurrence, or both.
Tumor assessments are performed until progressive disease or the participant withdrawal of 
consent. Tumor assessments will be stopped on s ubsequent start of new anticancer therapy, with 
the exception of starting adjuvant treatment described in Section  6.5.
[IP_ADDRESS] Neoadjuvant Rectal Score
The neoadjuvant rectal score (NAR) was developed by [CONTACT_249998] a 
short term clinical study surrogate endpoint (George 2015) . The Valentini nomograms 
(Valentini 2011)  to predict overall survival in rectal cancer patients after neoadjuvant treatment 
are the basis of the NAR score. Its score ranges from 0 to 100, whereas a score close to 100 is indicative of a poorer prognosis. 
The NAR formula includes the clinical tumor (cT) stage, pathologic tumor (pT), and node (pN) 
stage according to the tumor, node, metastasis classification system for colorectal cancers. The NAR formula is as follows:
NAR = [5 pN–3 (cT–pT) + 12]
2
9.61
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N66/1228.2 Safety Assessments and Procedures
The safety profile of the study intervention will be assessed through the recording, reporting and 
analysis of baseline medical conditions, AEs, physical examination findings, vital signs, and laboratory tests.
The safety observation is divided into the following periods:
!Baseline: safety evaluation before the initiation of study intervention
!Treatment Period: during study intervention
!Short-term Safety Follow-up: evaluations after the Treatment Period, including the 
perioperative and postoperative observation (until Week 19)
!Long-term Safety Follow-up: up to [ADDRESS_303851] already been followed up for more than 1 year (Long-term Safety or 
Survival Follow-up) will be discontinued from the study after the approval of protocol amendment version 4.0 by [CONTACT_249976].
Frequency of visits and specific procedures are described in  Table 1 and Table 2.
Comprehensive assessment of any potential toxicity experienced by [CONTACT_108097]. The Investigator will report any AEs, whether observed by [CONTACT_108098]; the reporting period is specified in Section 8.3.1 (Time Period and Frequency for 
Collecting Adverse Event and Serious Adverse Event Information).
8.2.1 Physical Examinations
A complete physical examination will be performed at Screening and a brief physical examination will be performed at all other time points indicated in the SoA (Section 1.3).
!A complete physical examination will include, at a minimum, assessments of the 
Cardiovascular, Respi[INVESTIGATOR_696], Gastrointestinal, and Neurological systems. Height (at Screening) and weight will also be measured and recorded.
!A brief physical examination will include, at a minimum, assessments of the skin, lungs, cardiovascular system, and abdomen.
!Investigators should pay special attention to clinical signs related to previous serious illnesses.
!Investigators will report findings in the irradiated area during the Short- and Long-term Safety Follow-up periods.
For participants with a change in body weight of at least 10% from baseline, individual 
capecitabine doses should be recalculated. See Section 6.1for details.
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N67/1228.2.2 Vital Signs
!Temperature, pulse rate, respi[INVESTIGATOR_697], and blood pressure will be assessed.
!Blood pressure and pulse measurements will be assessed in a semi-supi[INVESTIGATOR_103645] a 
completely automated device. Manual techniques will be used only if an automated device is not available.
!Blood pressure and pulse measurements should be preceded by [CONTACT_2669] [ADDRESS_303852] for the participant in a quiet setting without distractions (e.g. television, cell phones).
!Vital signs (to be taken before blood collection for laboratory tests) will consist of 1 pulse and 
3 blood pressure measurements ([ADDRESS_303853] 1 min). The average of the 3 blood pressure readings will be recorded on the CRF.
8.2.3 Electrocardiograms
Digital ECGs for all participants will be recorded at the site. Triplicate ECGs will be obtained for participants according to the Schedules of Activities (Table 1) .
Electrocardiograms will be documented by [CONTACT_249999]. All ECG results 
must be reviewed at the site by [CONTACT_29517] a medically qualified designee for clinical management of the participant. The Investigator will judge the overall interpretation as normal or abnormal. If abnormal, it will be decided if the abnormality is clinically significant or not clinically significant and the reason for the abnormality will be recorded on the eCRF. 
8.2.4 Clinical Safety Laboratory Assessments
!In woman of childbearing potential, pregnancy testing (serum β-human chorionic 
gonadotropin) will be performed at the visits specified in the SoA (Section 1.3). Participants 
after menopause (age-related amenorrhea ≥12 consecutive months) or participants who have 
undergone hysterectomy or bilateral oophorectomy are exempt from pregnancy testing.
!Blood and urine samples will be collected for the clinical laboratory tests listed in  Appendix 8,  
at the time points listed in the SoA (Section 1.3). All samples should be clearly identified.
!Additional tests may be performed at any time during the study, as determined necessary by [CONTACT_56861].
!The tests will be performed by [CONTACT_12082].
!The Sponsor must receive a list of the local laboratory normal ranges before shipment of study intervention(s). Any changes to the ranges during the study must be forwarded to the Sponsor or designated organization.
!The Investigator must review each laboratory report, document their review, and record any clinically relevant changes occurring during the study in the AE section of the CRF. The laboratory reports must be filed with the source documents.
!Analyte results that could unblind the study will not be reported to investigative sites or other blinded personnel until the study has been unblinded.
Nonfasting blood samples are acceptable for this study.
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N68/122SeeAppendix [ADDRESS_303854] of clinical laboratory assessments that will be performed. Further 
details will be provided in the Laboratory Manual.
8.2.5 Suicidal Risk Monitoring
Not applicable.
8.3 Adverse Events and Serious Adverse Events
The definitions of an AE and a serious adverse event (SAE) are in  Appendix 7.
8.3.1 Time Period and Frequency for Collecting Adverse Event and 
Serious Adverse Event Information
The AE reporting period for safety surveillance begins when the participant is initially included in 
the study (date of first signature [CONTACT_43998]/date of first signature [CONTACT_108166]) and continues until the final assessment at [ADDRESS_303855] be recorded and reported, as indicated in  Appendix 7,  only up to Week 27 in the long-term safety follow-up period.
The method of recording, evaluating, and assessing causality of AEs (including SAEs) and the 
procedures for completing and transmitting SAE reports are in  Appendix 7.
8.3.2 Method of Detecting Adverse Events and Serious Adverse 
Events
At each study visit, the participant will be quer ied on changes in his or her condition. During the 
reporting period, any unfavorable changes in the pa rticipant’s condition will be recorded as AEs, 
regardless if reported by [CONTACT_108101].
Complete, accurate and consistent data on all AEs experienced for the duration of the reporting 
period (defined below) will be reported on an ongoing basis in the appropriate section of the CRF. All SAEs must be additionally documented and reported using the appropriate Report Form as specified in  Appendix 7.
8.3.3 Follow-up of Adverse Events and Serious Adverse Events
Adverse events are recorded and assessed continuously throughout the study, as specified in 
Section 8.3.1 (Time Period and Frequency for Collecting Adverse Event and Serious Adverse 
Event Information) and are assessed for their outcome at the final assessment at [ADDRESS_303856] be monitored and followed-up by [CONTACT_108100], unless the participant is documented as “lost to follow-up”. Reasonable attempts to obtain this information must be made and documented. It is 
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N69/122also the responsibility of the Investigator to ensure that any necessary additional therapeutic 
measures and follow-up procedures are performed. Further information on follow-up procedures is given in Appendix 7 (Adverse Events: Definitions and Procedures for Recording, Evaluating, 
Follow-up, and Reports).
8.3.[ADDRESS_303857] comply with any applicable site-specific requirements related to the 
reporting of SAEs (particularly deaths) involving study participants to the Independent Ethics Committee (IEC)/Institutional Review Board (IRB) that approved the study.
In accordance with International Council for Harmonisation (ICH) Good Clinical Practice (GCP), 
the Sponsor/designee will inform the Investigator of findings that could adversely affect the safety 
of participants, impact the conduct of the study or alter the IEC’s/IRB’s approval/favorable opi[INVESTIGATOR_43932]. In line with respective regulations, the Sponsor/designee will inform the Investigator of AEs that are both serious and unexpected and considered to be related to the administered product (“suspected unexpected serious adverse reactions” or S[LOCATION_003]Rs). The Investigator should place copi[INVESTIGATOR_43933]. National regulations regarding Safety Report notifications to Investigators will be considered.
When specifically required by [CONTACT_43973], the Sponsor/designee will provide 
appropriate Safety Reports directly to the concerned lead IEC/IRB and will maintain records of these notifications. When direct reporting is not clearly defined by [CONTACT_108103]-specific 
regulations, the Investigator will be responsible for promptly notifying the concerned IEC/IRB of 
any Safety Reports provided by [CONTACT_1034]/designee and of filing copi[INVESTIGATOR_43934].
For studies covered by [CONTACT_43975] 2001/20/EC, the Sponsor’s responsibilities 
regarding the reporting of SAEs/S[LOCATION_003]Rs/Safety Issu es will be carried out in accordance with that 
Directive and with the related Detailed Guidance documents.
8.3.5 Pregnancy
Only pregnancies the Investigator considers to be related to the study intervention (e.g. resulting from a drug interaction with a contraceptive method) are AEs. However, all pregnancies with an estimated conception date during the period defined in Section 8.3.1 (Time Period and Frequency 
for Collecting Adverse Event and Serious Adverse Event Information) must be recorded in the AE page/section of the CRF for both pregnancies in female participants and pregnancies in female partners of male participants. The Investigator must notify the Sponsor/designee in an expedited manner of any pregnancy using the Pregnancy Report Form, which must be transmitted by [CONTACT_250000] 7,  section on Reporting Serious Adverse 
Events, Adverse Events of Special Interest, and Dose Limiting Toxicities.
Investigators must actively follow-up, document and report on the outcome of all these 
pregnancies, even if the participants are withdrawn from the study.
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N70/122The Investigator must notify the Sponsor/designee of these outcomes using the Pregnancy Report 
Form. If an abnormal outcome occurs, the SAE Report Form will be used if the participant sustains an event and the Parent-Child/Fetus Adverse Event Report Form if the child/fetus sustains an event. Any abnormal outcome (e.g. spontaneous abortion, fetal death, stillbirth, congenital anomalies, ectopic pregnancy) must be reported in an expedited manner, as specified in Section 8.3.1,  while normal outcomes must be reported within [ADDRESS_303858] be 
discontinued from study intervention. The Sponsor/designee must be notified without delay and the participant must be followed as indicated above.
8.4 Treatment of Overdose
For this study, any dose of peposertib greater than 100% of the planned dose will be considered an overdose.
The Sponsor does not recommend specific treatment for an peposertib overdose. The Investigator 
should use clinical judgment to manage any overdose considering the presenting symptoms and standard evaluation results.
For this study, any dose of capecitabine greater than 100% of the planned dose will be considered 
an overdose.
Overdose of capecitabine generally results in severe forms of normally occurring adverse 
reactions. Investigators are asked to check the respective information in the Product Information/SmPC for further advice.
Even if it not associated with an AE or a SAE, any overdose is recorded in the CRF and reported 
to drug safety in an expedited manner. Overdoses are reported on a SAE Report Form, following the procedure in Appendix 7,  section on Reporting Serious Adverse Events, Adverse Events of 
Special Interest, and Dose Limiting Toxicities.
8.5 Pharmacokinetics
!The following PK parameters will be calculated, when appropriate:
Symbol Definition
Cmax Maximum observed concentration.
Tmax The time to reach the maximum observed concentration collected during a dosing interval (unless 
otherwise defined, take the first occurrence if multiple/identical C maxvalues).
AUC 0-t The AUC from time zero (= dosing time) to the last sampling time (t last) at which the concentration 
is at or above the lower limit of quantification. Calculated using the mixed log linear trapezoidal rule (linear up, log down).
AUC
0-24 The AUC from time zero (= dosing time) to [ADDRESS_303859] dose. Calculated using the mixed log linear 
trapezoidal rule (linear up, log down).
AUC 0-∞ The AUC from time zero (= dosing time) to infinity post dose. Calculated using the mixed log linear 
trapezoidal rule (linear up, log down).
T1/2 Apparent terminal half-life. T 1/2=l n( 2 ) /λz
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N71/122Symbol Definition
CL/f The apparent total body clearance of study intervention following extravascular administration on 
FD1, taking into account the fraction of dose absorbed.
CL/f = Dose p.o./AUC 0-∞. The predicted AUC 0-∞should be used.
Vz/f The apparent volume of distribution during the terminal phase following extravascular 
administration, based on the fraction of dose absorbed. V z/f = Dose/(AUC 0-∞*λz) following single 
dose. V z/f = Dose/(AUC ∀*λz) following multiple dose.
Racc(Cmax) The accumulation factor to assess the increase in maximum concentration from FD1 to FD9. 
Racc(Cmax)=( C maxFD9)/(C maxFD1).
Racc(AUC 0-24) The accumulation factor to assess the increase in exposure from FD1 to FD9 during time 0 to 24 h. 
Racc(AUC 0-24) = (AUC 0-24FD9)/(AUC 0-24FD1).
Racc(AUC 0-t) The accumulation factor to assess the increase in exposure from FD1 to FD9 during time 0 to t h. 
Racc(AUC 0-t) = (AUC 0-tFD9)/(AUC 0-tFD1).
LI The linearity index after repeated administration calculated as LI= (AUC 0-24 after multiple dose (at 
steady state)) / (AUC 0-∞after single dose)
AUC=area under the concentration-time curve, FD=fraction day.
!Whole blood samples of approximately [ADDRESS_303860] ed for measurement of plasma
concentrations of peposertib (and/or metabolites), capecitabine, and capecitabine metabolites.Collection times are specified in the SoA (Table 4) . PK sampling should be performed 
within ± [ADDRESS_303861] 2 h of sample collection, within ± 20 min for the 3 h and 4 h sample, and within ± 30 min for the 6 h sample. The predose sample(s) should be collected prior to capecitabine and peposertib administration but within 60 min prior to the peposertibadministration. A maximum of 3 samples per participant may be collected at additional time points during the study if warranted and agreed  upon between the Investigator and the Sponsor. 
The actual date and time (24 h clock time) of each sample will be recorded to calculate actual time elapsed since prior dose administration. The sampling timing may be altered during the study based on newly available data (e.g. to obtain data closer to the time of peak plasma concentrations) to ensure appropriate monitoring.
!The quantification of peposertib, capecitabine and capecitabine metabolites in plasma will be performed using a validated liquid chromatography-tandem mass spectrometry method. Concentrations will be used to evaluate PK of peposertib (and/or metabolites) and capecitabine.
!Remaining samples collected for analyses of peposertib and capecitabine (whole blood) concentration may also be used to evaluate saf ety and efficacy aspects related to concerns 
arising during or after the study.
!Details on processes for collection and shipment of these samples are in the Laboratory Manual. Retention time and possible analyses of samples after the end of study are specified in the respective ICF.
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N72/122 CCI
CCICCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N73/122 CCI
CCICCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N74/1228.[ADDRESS_303862] the 
SMC in dose recommendations. The planned cohort size is 3 participants. The total sample size will depend on the number of cohorts to be evaluated. It is anticipated that 18 to 30 evaluable participants are required.
9.3 Populations for Analyses
The analysis populations are specified below (Table 11) .
CCI
CCICCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N75/122Table [ADDRESS_303863] 80% of peposertib, 50% of capecitabine, and 80% of RT planned dose and complete the DLT period. The DE set will also include participants treated in dose escalation cohorts who experience a DLT during the DLT period regardless of the 
amount of each study intervention received/completion of the DLT period.
FAS/SAF The FAS/SAF will include all participants who are enrolled in the study and received at 
least [ADDRESS_303864] 1 quantifiable plasma concentration at a scheduled PK time point postdose.
cCR=Clinical Complete Response, DE=Dose Escalation, DLT=dose limiting toxicity, FAS=Full Analysis Set, PK=Pharmacokinetic, RT=radiotherapy, SAF=Safety.
9.4 Statistical Analyses
The following statistics will be used to summarize the study data (e.g. Baseline characteristics) 
unless otherwise specified:
!Continuous variables: number of nonmissing observations, mean, standard deviation, median, 
minimum, and maximum, 95% CIs for the mean, as appropriate.
!Categorical variables: frequencies and percentages.
9.4.1 Efficacy Analyses
Statistical analysis methods for efficacy endpoints are described in  Table 12.
Table 12 Statistical Analysis Methods for Efficacy Endpoints
Endpoint Statistical Analysis Methods
Secondary
Composite endpoint of 
pCR/cCRDerivation of the pCR/cCR composite endpoint (pCR based on local review) is 
described in Section 3.1.
The proportion of participants with pCR/cCR is indicated together with the 
95%-Clopper-Pearson CI. The analysis will be performed on the FAS.
Disease-Free Survival Disease-free Survival time, defined as the time from first treatment day to the date of 
the first documentation of objective progressive disease or death due to any cause, whichever occurs first.
The analysis will be performed as described below for time-to-event endpoints.
pCR The definition of pCR is provided in Section 3.1.
pCR will be analyzed once on the local review of the histology slides.The proportion of participants with pCR will be reported together with the 
corresponding 95% CIs. 
The analysis will be performed on the FAS
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N76/122Endpoint Statistical Analysis Methods
cCR The definition of cCR is provided in Section 3.1.
The proportion of participants with cCR will be reported together with the 
corresponding 95% CIs. 
The analysis will be performed on the FAS
Local/distant recurrence The following analyses will be performed:
!Time from surgery to local recurrence
!Time from surgery to distant recurrence.
The analyses will be performed as described below for time-to-event endpoints.
Neoadjuvant Rectal 
ScoreThe neoadjuvant rectal score will be presented in terms of summary statistics (such 
as mean, median, standard deviation, and quartiles) and graphically.
The analysis will be performed on the FAS Population.
cCR=Clinical Complete Response, CI=confidence interv al, CR=complete response, FAS=Full Analysis Set, 
pCR=Pathological Complete Response.
In addition to analyses specified in Table 12,  for the primary and main secondary endpoints 
subgroup analyses on baseline variables such as gender, tumor stage, etc. will be performed. 
Analysis of Time-to-event Endpoints
Kaplan-Meier estimates will be presented together with a summary of associated statistics (median 
survival time and survival rate estimates) including the corresponding 2-sided 95% CIs. Confidence intervals for the median will be calculated according to Brookmeyer and Crowley (Brookmeyer 1982) and CIs for the survival function estimates will be derived using the log-log 
transformation according to Kalbfleisch and Prentice (Kalbfleisch 1980) . The estimate of the 
standard error will be computed using Greenwood’s formula.
9.4.2 Safety Analyses
Statistical analysis methods for safety endpoints are described in  Table 13.
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N77/122Table 13 Statistical Analysis Methods for Safety Endpoints
Endpoint Statistical Analysis Methods
Primary
Occurrence of DLTs The number and proportion of participants experiencing a DLT confirmed by [CONTACT_250001].
Analysis will be based on the DE Analysis Set.
Secondary
Occurrence of TEAEs
and treatment-related AEs according to the CTCAE version 5.0All AEs will be coded according to the MedDRA, version 21.0 or higher. The severity 
of AEs will be graded using NCI-CTCAE v5.0 toxicity grades.
Adverse events related to study intervention will be defined as any AE considered 
related to any study intervention. In addition, missing classifications concerning study intervention relationships will be considered related to the study intervention(s).
Adverse events observed from the first dose until [ADDRESS_303865] study intervention
administration (i.e. TEAEs) will be summarized according to MedDRA system organ 
classes and preferred terms. The incidence and type of the following will be analyzed:
!TEAEs and SAEs
!TEAEs and SAEs related to study intervention
!TEAEs with NCI-CTCAE Grades ≥3
!TEAEs related to study intervention with NCI-CTCAE Grades ≥3
!AEs leading to withdrawal, dose modifications, or permanent study intervention
discontinuation
!Deaths and reasons for death will be tabulated. In addition, deaths within [ADDRESS_303866] dose administration and deaths beyond this period up to 90 days follow-up and reasons for death will be tabulated.
Analyses will be based on the Safety Analysis Set.
Occurrence of 
abnormalities (Grade≥3) in laboratory 
test values and markedly 
abnormal vital sign measurements, andclinically significantly 
abnormal ECGs 
including clinically important increases in QT interval (QTcF)Laboratory results will be classified by [CONTACT_250002]-CTCAE v5.0. The 
worst on-study grades after the first study intervention will be summarized.
Shifts in toxicity grades from first treatment to highest grade will be displayed. Results 
for variables that are not part of NCI-CTCAE will be presented as below, within, or above normal limits. Only participants with postbaseline laboratory values will be 
included in these analyses.
Physical examination, including vital signs (body temperature, respi[INVESTIGATOR_697], pulse
rate, and blood pressure), and 12-lead ECG, recorded at baseline and after administration of study intervention.
Analyses will be based on the Safety Analysis Set.
AE=adverse event, DLT=dose limiting toxicity, ECG=electrocardiogram, MedDRA=Medical Dictionary for Regulatory 
Activities, NCI-CTCAE=National Cancer Institute Common Terminology Criteria of Adverse Events, SAE=serious 
adverse event, SMC=Safety Monitoring Committee, TEAE=treatment-emergent adverse event.
Analyses for SMC Meetings:
During dose escalation the analysis will focus on safety and available PK data.
The Bayesian escalation approach will be applied to assist the SMC in the choice of the next dose 
level. The SMC will receive results of a Bayesian 2-parameter dose-toxicity model with overdose control, updated with the observed DLT data. The recommended next dose level will minimize the Bayesian Risk among all considered dose levels, while at the same time limiting the risk of overdose or excessive toxicity (Neuenschwander 2008) . The target toxicity is 30%. Details of the 
model including the prior distribution and toxicity regions are described in Appendix 10.
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N78/122The following peposertib dose levels will be considered for escalation decisions: 30, 50, 100, 200, 
400, 600, and 800 mg; 50 mg is the starting dose. Dose increases will not exceed 100% of the highest dose level considered safe at the time of escalation decision. The SMC may decide to deviate from the suggestion of the Bayesian escalation approach. Also, the SMC may decide to change the dosing regimen. In such a case the model will be extended, or a separate model will be set up.
Analyses for the Bayesian dose escalation will be performed on the DE Analysis Set. Usually 
decisions on dose escalation are taken once all participants of the most recent cohort have completed the DLT period or dropped out. In exceptional cases, however, the SMC may decide on the next cohort earlier, i.e. before the last participant of a cohort has finished the DLT period (considering the model recommendation and risk of overdose). Per definition of the DLT analysis, participants who have not completed the DLT period are not included for update of the model, unless they experienced a DLT. However, such participants will be included at next SMC (if criteria for the DE Analysis Set are fulfilled).
Details on analyses for SMCs/CSR will be described in the corresponding SAP.
9.4.3 Other Analyses
Baseline Characteristics
Baseline characteristics will be tabulated as described in Section 9.4.
The PK,  analyses will be specified in the Integrated Analysis Plan 
finalized before database lock. Integrated analyses across studies, such as the population PK analysis  will be presented separately from the main CSR.
CCI
CCICCI
CCICCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N79/1229.4.4 Sequence of Analyses
The following analyses will be performed:
To decide on dose escalation, safety and PK analyses will be provided for the purpose of SMC 
meetings. The cut-off for dose escalation assessments by [CONTACT_250003] (or dropout) of the last participant in the respective dose escalation 
cohort of usually [ADDRESS_303867].
Additional analyses might be performed, e.g. for publication purposes.Follow-up analyses to report further efficacy and safety data will be done at the End of Study.More details will be described in the Integrated Analysis Plan.
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N80/[ZIP_CODE] References
Amin MB, Edge SB, Greene FL, et al, eds. AJCC Cancer Staging Manual. 8thed. [LOCATION_001]:
Springer 2017.
Brookmeyer R and Crowley J. A confidence interval for the median survival time. Biometrics.
1982;38:29-41.
Cockcroft DW and Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron.
1976;16:31-41.
Curtin NJ. DNA repair dysregulation from cancer driver to therapeutic target. Nat Rev Cancer.
2012;12:801-17.
Dewdney A, Cunningham D, Tabernero J, et al. Multicenter randomized phase II clinical trial 
comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by [CONTACT_250004]-risk rectal cancer (EXPERT-C). J Clin Oncol. 2012 May 10;30(14):1620-7.
Ferrari L and Fichera A. Neoadjuvant chemora diation therapy and pathological complete response 
in rectal cancer. Gastroenterol Rep (Oxf). 2015;3(4):277-88.
Furgason JM and Bahassi EM. Targeting DNA repair mechanisms in cancer. Pharmacol Ther.
2013;137:298-308.
George Jr TJ, Allegra CJ, Yothers G. Neoadjuvant Rectal (NAR) Score: a new surrogate endpoint 
in rectal cancer clinical trials. Curr Colorectal Cancer Rep. 2015;11(5):275-80.
Gérard JP, Chamorey E, Gourgou-Bourgade S, et al. Clinical complete response (cCR) after 
neoadjuvant chemoradiotherapy and conservative treatment in rectal cancer. Findings from the ACCORD 12/PRODIGE 2 randomized trial. Radiother Oncol. 2015;115(2):246-52.
Glynne-Jones R, Wyrwicz L, Tiret E, et al. Rectal Cancer: ESMO Clinical Practice Guidelines for 
diagnosis, treatment and follow-up. Ann Oncol. 2017;28(4):iv22-iv40.
Kalady MF, de Campos-Lobato LF, Stocchi L, et al. Predictive factors of pathologic complete 
response after neoadjuvant chemoradiation for rectal cancer. Ann Surg. 2009;250(4):582-9.
Kalbfleisch JD and Prentice RL. The statistical analysis of failure time data, [LOCATION_001]: John 
Wiley & Sons 1980.
Kwok TT and Sutherland RM. Enhancement of sensitivity of human squamous carcinoma cells to 
radiation by [CONTACT_14198][INVESTIGATOR_5169]. J Natl Cancer Inst. 1989;81(13):1020-4.
Liu GC, Yan JP, He Q, et al. Effect of neoadjuva nt chemoradiotherapy with capecitabine versus 
fluorouracil for locally advanced rectal cancer: a meta-analysis. Gastroenterol Res Pract.
2016;2016:1798285.
Longley DB, Harkin DP and Johnston PG. 5-fluorouracil: mechanisms of action and clinical 
strategies. Nat Rev Cancer. 2003;3(5):330-8.
Maas M, Nelemans PJ, Valentini V, et al. Long-term outcome in patients with a pathological 
complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 2010;11(9):835-44.
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N81/122Maas M, Lambregts D MJ, Nelemans PJ, et al. Assessment of clinical complete response after 
chemoradiation for rectal cancer with digital rectal examination, endoscopy, and MRI: Selection for organ-saving treatment. Ann Surg Oncol. 2015; 22(12):3873-80.
Martos CF, Pericay C, Losa F, et al. Eff ect of Aflibercept plus modified FOLFOX6 induction 
chemotherapy before standard chemoradiotherapy and surgery in patients with high-risk rectal adenocarcinoma The GEMCAD 1402 randomized clinical trial. JAMA Oncol. 2019;5(11):1566-73.
Mosteller RD. Simplified calculation of body-surface area. N Eng J Med. 1987;317(17):1098.Neuenschwander B, Branson M and Gsponer T. Critical aspects of the Bayesian approach to 
phase I cancer trials. Statist Med. 2008;27(13):2420-39.
Parfitt JR and Driman DK. The total mesorectal excision specimen for rectal cancer: a review of 
its pathological assessment. J Clin Pathol. 2007;60(8):849-55.
Petrelli F, Trevisan F, Cabiddu M, et al. Total neoadjuvant therapy in rectal cancer: A systematic 
review and meta-analysis of treatment outcomes. Ann Surg. 2020;271(3):440-48.
Pi[INVESTIGATOR_1946] C, Di Bisceglie M, Di Fabio F, et al. Ph ase II study of preoperative treatment with external 
radiotherapy plus panitumumab in low-risk, locally advanced rectal cancer (RaP Study/STAR-03). 
Oncologist. 2018;23(8):912-18. 
Ridgway PF and Darzi AW. The role of total mesorectal excision in the management of rectal 
cancer. Cancer Control. 2003;10(3):205-11.
Rödel C, Graeven U, Fietkau R, et al; German  Rectal Cancer Study Group. Oxaliplatin added to 
fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2015;16(8):979-89.
Roxburgh CSD, Strombom P, Lynn PB, et al. Influence of timing of surgery on perioperative 
morbidity after neoadjuvant therapy for lo cally advanced rectal cancer. J Clin Oncol.
2018;36(4):abstr 754.
Sanghera P, Wong DW, McConkey CC, et al. Chemoradiotherapy for rectal cancer: an updated 
analysis of factors affecting pathological response. Clin Oncol (R Coll Radiol). 2008;20(2):176-83.
Schulz N, Chaachouay H, Nytko KJ, et al. Dyn amic in vivo profiling of DNA damage and repair 
after radiotherapy using canine patients as a model. Int J Mol Sci. 2017;18(6):1176.
Shahab D, Gabriel E, Attwood K, et al. Adjuvant chemotherapy is associated with improved 
overall survival in locally advanced rectal cancer after achievement of a pathologic complete response to chemoradiation. Clin Colorectal Cancer. 2017;16(4):300-7.
Siegel LR, Miller KD and Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67(1):7-30.Sweeting M, Mander A and Sabin T. bcrm: Bayesian continual reassessment method designs for 
Phase I dose-finding trials. J Stat Softw. 2013;54(13):1-26.
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N82/122Tulchinsky H, Shmueli E, Figer A, et al. An in terval >7 weeks between neoadjuvant therapy and 
surgery improves pathologic complete response and disease-free survival in patients with locally advanced rectal cancer. Ann Surg Oncol. 2008;15(10):2661-7.
Valentini V, van Stiphout RG, Lammering G, et al. Nomograms for predicting local recurrence, 
distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials. J Clin Oncol. 2011;29(23):3163-72.
Valentini V, Gambacorta MA, BarbaroB, et al. International consensus guidelines on clinical 
target volume delineation in rectal cancer. Radiother Oncol. 2016;120(2):195-201.
Washington MK, Berlin J, Branton P, et al. Protocol for the examination of specimens from 
patients with primary carcinoma of the colon and rectum. Arch Pathol Lab Med.2009;133(10):1539-51.
Zeng WG, Zhou ZX, Liang JW, et al. Impact of interval between neoadjuvant chemoradiotherapy 
and surgery for rectal cancer on surgical and oncologic outcome. J Surg Oncol. 2014;110(4):463-7.
Zheng J, Feng X, Hu W et al. Systematic review and meta-analysis of preoperative 
chemoradiotherapy with or without oxaliplatin in locally advanced rectal cancer. Medicine. 2017;96(13): e6487.
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N83/[ZIP_CODE] Appendices
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N84/122Appendix [ADDRESS_303868] Computerized tomography
CTCAE Common Terminology Criteria of Adverse Events
ctDNA Circulating tumor DNA
CTV Clinical target volume
CYP Cytochrome
DLT Dose limiting toxicity
DNA-PK DNA-protein kinase
DRE Digital rectal examination
DSB Double-strand break
ECG Electrocardiogram
eCRF Electronic Case Report Form
EUS Endoscopic ultrasonography
FD Fraction day
Gy Gray
GCP Good Clinical Practice
HRT Hormonal replacement therapy
ICF Informed Consent Form
ICH International Council for Harmonisation
IEC Independent Ethics Committee
IR Ionizing radiation
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N85/122IRB Institutional Review Board
IVRS Interactive Voice Response System
IWRS Interactive Web Response System
MRI Magnetic resonance imaging
MTD Maximum tolerated dose
NAR Neoadjuvant rectal score
NCCN National Comprehensive Cancer Network
NCI National Cancer Institute
OAR Organs at risk
pCR Pathological Complete Response
PK Pharmacokinetic(s)
PPI [INVESTIGATOR_249968]2D Recommended Phase II dose
RT Radiotherapy
SAE Serious adverse event
SMC Safety Monitoring Committee
SmPC Summary of Product Characteristics
SoA Schedule of Activities
SoC Standard of care
S[LOCATION_003]R Suspected Unexpected Serious Adverse Reactions
TME Total mesorectal excision
ULN Upper limit of normal
5FU 5-fluorouracil
CCI
CCICCI CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N86/122Appendix 2 Study Governance
Financial Disclosure
Investigators and Sub-Investigators will provide the Sponsor with sufficient, accurate financial 
information, as requested, for the Sponsor to submit complete and accurate financial certification or disclosure statements to the appropriate regulatory authorities. This information is required 
during the study and for 1 year after completion of the study.
Informed Consent Process
!The Investigator or his/her representative will explain the nature of the study to the participant 
or his/her legally authorized representative (where allowed by [CONTACT_10976]) and answer all questions on the study.
!Participants must be informed that their participation is voluntary.
!Participants or their legally authorized representative (where allowed by [CONTACT_10976]) will be required to sign a statement of informed consent that meets the requirementsof 21 CFR 50; local regulations; ICH guidelines; Health Insurance Portability and Accountability Act (HIPAA) requirements, where applicable; and the IRB/IEC or study center.
!The medical record must include a statement that written informed consent was obtained before the participant was enrolled in the study and the date the written consent was obtained. The authorized person obtaining the informed consent must also sign the ICF.
!If the ICF is updated during their participation in the study, participants must be re-consented to the most current, approved version.
!A copy of the ICF(s) must be provided to the participant or the participant’s legally authorized representative.
!The original signed and dated consent will remain at the Investigator’s site and must be safely 
archived so that it can be retrieved at any time for monitoring, auditing and inspection purposes.
!Participants who are rescreened are required to sign a new ICF.
Data Protection
!The Sponsor will assign a unique identifier to participants after obtaining their informed 
consent. All participant records or datasets transferred to the Sponsor will contain the identifier only; participant names or any identifiable information will not be transferred.
!The Sponsor must inform participants that their  personal study-related data will be used per 
local data protection and privacy laws. The level of disclosure must also be explained to the participant.
!The participant must be informed that his/her medical records may be examined by [CONTACT_250005]-appointed, authorized personnel, by [CONTACT_6667]/IEC members, and by [CONTACT_108111]. All such persons will strictly maintain participants’ confidentiality.
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N87/122!The Investigator will complete the participant registration using the IVRS/IWRS 
(Section 6.3.1) . If the participant meets all inclusion criteria and does not meet any of the 
exclusion criteria, the participant will be regis tered by [CONTACT_54537]/IWRS. If the participant is 
ineligible for the study, a participant number will be allocated and documented.
Study Administrative
This clinical study will be sponsored by [CONTACT_28794], [LOCATION_013] (in all countries except the [LOCATION_003]
and Canada) and EMD Serono Research & Development Institute, Inc. (EMD Serono R&D), [LOCATION_003], for sites in the [LOCATION_003] and Canada.
Site and country selection will be based on historic enrollment data and the results of a feasibility 
assessment. It is planned to open the dose escalation part in approximately 10 sites in the US and Europe. Sites will include clinical centers and academic centers, mostly in an outpatient setting.
The Coordinating Investigator [INVESTIGATOR_107917], per ICH GCP. The Coordinating Investigator [INVESTIGATOR_107918].
The study will appear in the following clinical studies registries: EudraCT (2018-002275-18) and 
ClinicalTrials.gov.
An SMC will be formed in this study and will review all available safety data on a regular basis 
during the study. The SMC consists of Sponsor representatives (including, but not limited to the Medical Responsible, the Patient Safety Strategy Lead, the Biostatistician, and the PK expert) and 
Investigators. The Medical Monitor from the Contract Research Organization will be a SMC member.
The SMC will be responsible for dose escalation decisions, continuous safety assessment, and will 
provide input into the selection of a RP2D. The full membership, mandate, and processes of the SMC will be detailed in the SMC charter.
After each cohort has finished the peposertib tr eatment period (DLT period), the SMC will review 
the safety, tolerability, and PK data and will provi de recommendations for the next cohort, move 
to the next dose level, stay on the actual dose level,  de-escalate to a lower dose level, or explore 
alternative schedules of peposertib. In addition, th e SMC will review safety, tolerability, and PK 
data when each cohort has finished the 30-day fo llow-up period after surgery to provide further 
recommendations on dose escalation.
Details of structures and associated procedures will be defined in separate SMC charters. 
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N88/122Regulatory and Ethical Considerations
!This study will be conducted in accordance with the protocol and the following:
oConsensus ethical principles derived from international guidelines, including the 
Declaration of Helsinki and Council for International Organizations of Medical Sciences (CIOMS) International Ethical Guidelines
oApplicable ICH GCP Guidelines
oApplicable laws and regulations.
!The Investigator must submit the protocol, protocol amendments (if applicable), ICF, 
Investigator Brochure, and other relevant documents to an IRB/IEC and the IRB/IEC must review and approve them before the study is initiated.
!Any protocol amendments (i.e. changes to the protocol) will be documented in writing and require IRB/IEC approval before implementation of changes, except for changes necessary to eliminate an immediate hazard to study participants. When applicable, amendments will be submitted to the appropriate Health Authorities.
!The Investigator will be responsible for the following:
oProviding written summaries of the status of the study to the IRB/IEC annually or 
more frequently per the IRB’s/IEC’s requirements, policies, and procedures
oNotifying the IRB/IEC of SAEs or other significant safety findings, as required by 
[CONTACT_1744]/IEC procedures
oProviding oversight of the study conduct at the site and adherence to requirements 
of 21 CFR, ICH guidelines, the IRB/IEC, European regulation 536/2014 for clinical studies (if applicable), and all other applicable local regulations.
!The protocol and any applicable documentation will be submitted or notified to the Health Authorities in accordance with all local and national regulations for each site.
Emergency Medical Support
!The Sponsor or designee will provide Emergency Medical Support cards to participants for use 
during the study. These provide the means for participants to identify themselves as participating in a clinical study. Also, these give health care providers access to any information about this participation that may be needed to determine the course of medical treatment for the participant. The information on the Emergency Medical Support card may include the process 
for emergency unblinding (if applicable).
!The first point of contact [CONTACT_250006]. Consequently, the Investigator agrees to provide his or her emergency contact 
[CONTACT_108117]. If the Investigator is available when an event occurs, they will answer any questions. Any subsequent action (e.g. unblinding) will follow the standard process established for Investigators.
!When the Investigator is not available, the Sponsor provides the appropriate means to contact a Sponsor physician. This includes provision of a 24-h contact [CONTACT_108118] a call center, whereby [CONTACT_250007]/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N89/122the medical emergency and to provide support for the potential unblinding of the participant 
concerned.
Clinical Study Insurance and Compensation to Participants
Insurance coverage will be provided for each country participating in the study. Insurance 
conditions shall meet good local standards, as applicable.
Clinical Study Report
After study completion, the Sponsor will write a CSR in consultation with the Coordinating 
Investigator, and other relevant committees or groups.
Publication
!The results of this study may be published or presented at scientific meetings. If this is foreseen, 
the Investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows [COMPANY_006] to protect proprietary information and to provide comments.
!The Sponsor will comply with the requirements for publication of study results. Per standard editorial and ethical practice, the Sponsor will generally support publication of multicenter studies only in their entirety and not as i ndividual site data. In this case, a Coordinating 
Investigator [INVESTIGATOR_249969].
!Authorship will be determined by [CONTACT_250008].
!Procedures for publication planning and the use of professional writers are not yet known. Questions may be directed to the Sponsor Medical Responsible.
Dissemination of Clinical Study Data
After completion of the study, a CSR will be written by [CONTACT_108122] [INVESTIGATOR_107920] E3, and will be submitted in accordance with local regulations.
Any and all scientific, commercial, and technical information disclosed by [CONTACT_108123]. The Investigator shall hold such information in confidence and shall not disclose the information to any third party except to such of the Investigator’s employees and staff as have been made aware that the information is confidential and who are bound to treat it as such and to whom disclosure is necessary to evaluate that information. The Investigator shall not use such information for any purpose other than for determining mutual interest in performing the study and, if the parties decide to proceed with the study, for the purpose of conducting the study.
The Investigator understands that the information de veloped from this clinical study will be used 
by [CONTACT_108124], to the US Food and Drug Administration, and to other government agencies. The Investigator also understands that, to allow for the use of the 
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N90/122information derived from the clinical study, the Investigator has the obligation to provide the 
Sponsor with complete test results and all data developed in the study.
No publication or disclosure of study results will be permitted except under the terms and 
conditions of a separate written agreement.
Data Quality Assurance
!All participant study data will be recorded on printed or eCRFs or transmitted to the Sponsor 
or designee electronically (e.g. laboratory data). Th e Investigator is responsible for verifying 
that data entries are complete, accurate, legible, and timely by [CONTACT_1189]. Details for managing CRFs are in the Clinical Operations Manual and the Data Management Guidelines.
!The Investigator must maintain accurate documentation (source data) that supports the information in the CRF.
!The Investigator must permit study-related monitoring, quality assurance audits, IRB/IEC review, and regulatory agency inspections and provi de direct access to the study file and source 
data.
!Monitoring details describing strategy (e.g. risk-based initiatives in operations and quality such as Risk Management and Mitigation Strategies and Analytical Risk-Based Monitoring), methods, responsibilities and requirements, including handling of noncompliance issues and monitoring techniques (central, remote, or on-site monitoring) are in the Monitoring Plan or contracts.
!The Sponsor or designee is responsible for data management of this study, including quality checking of the data and maintaining a validated database. Database lock will occur once quality control and quality assurance procedures have been completed. PDF files of the CRFs will be provided to the Investigators at study completion.
!Study monitors will perform ongoing source data verification to confirm that data in the CRF are accurate, complete, and verifiable; that the safety and rights of participants are being protected; and that the study is being conducted per the currently approved protocol and any other study agreements, ICH GCP, and all applicable regulatory requirements.
!Records and documents, including signed ICFs, pertaining to the conduct of this study must be retained by [CONTACT_13177] 15 years after study completion, unless local regulations, 
institutional policies, or the Sponsor requires a longe r retention. No records may be destroyed 
during the retention period without the Sponsor’s written approval. No records may be transferred to another location or party without the Sponsor’s written notification.
Source Documents
!Source documents provide evidence for the existence of the participant and substantiate the 
integrity of the data collected.
!The Investigator must keep a paper or electronic file (medical file and original medical records) at the site for each study participant. The file must identify each participant, contain the 
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N91/122following demographic and medical information for the participant, and should be as complete 
as possible:
oParticipant’s full name, date of birth, sex, height, and weight
oMedical history and concomitant diseases
oPrior and concomitant therapi[INVESTIGATOR_014] (including changes during the study)
oStudy identifier (i.e. the Sponsor’s study number) and participant’s study number
oDates of entry into the study (i.e. signature [CONTACT_108167]) and each 
visit to the site
oAny medical examinations and clinical findings predefined in the protocol
oAll AEs
oDate that the participant left the study, including any reason for early withdrawal 
from the study or study intervention, if applicable.
!All source data must be filed (e.g. CT or MRI scan images, ECG recordings, and laboratory results). Each document must have the participant number and the procedure date; ideally, printed by [CONTACT_250009]. As necessary, medical evaluation of these records should be performed, documented, signed and dated by [CONTACT_737].
!Data recorded on printed or electronic CRFs that ar e transcribed from source documents must 
be consistent with the source documents or the discrepancies must be explained. The Investigator may need to request previous medical records or transfer records, depending on the study. Also, current medical records must be available.
!The study monitors will use printouts of electronic files for source data verification. These printouts must be signed and dated by [CONTACT_737], and kept in the study file.
!Source documents are stored at the site for the longest possible time permitted by [CONTACT_1729], and/or as per ICH GCP guidelines, whichever is longer. The Investigator ensuresthat no destruction of medical records is performed without the Sponsor’s written approval.
!Definition of what constitutes source data is found in the eCRF guidelines.
Study Start and Site Start and Closure
First Act of Recruitment
!The first act of recruitment is the signing of the ICF and will be the study start date.
Study Closure and Site Termination
!The Sponsor reserves the right to close the study site or terminate the study at any time and for 
any reason. Study sites will be closed upon study completion. A study site is considered closed when all required documents and study supplies have been collected and a site closure visit has been completed.
!The Investigator may initiate site closure at any time, provided there is reasonable cause and sufficient notice is given in advance of the intended termination.
!Reasons for the early closure of a study site by [CONTACT_108129]:
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N92/122oFailure of the Investigator to comply with the protocol, the requirements of the 
IRB/IEC or local Health Authorities, the Sponsor's procedures, or GCP guidelines
oInadequate recruitment of participants by [CONTACT_108130]’s compound.
!If the study is prematurely terminated or suspended, the Sponsor will promptly inform the 
Investigators, the IECs/IRBs, the regulatory authorities, and any contract research organization(s) used in the study of the reason for termination or suspension, as specified by [CONTACT_1214]. The Investigator will promptly inform the participants and assure appropriate participant therapy and/or follow-up.
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N93/122Appendix 3 Contraception
Definitions:
Woman of Childbearing Potential
A woman is considered fertile following menarche and until becoming postmenopausal unless 
permanently sterile, as specified below.
If fertility is unclear (e.g. amenorrhea in adolescents or athletes) and a menstrual cycle cannot 
be confirmed before the first dose of study intervention, consider additional evaluation.
A woman of childbearing potential is not:
1. Premenarchal2. A premenopausal female with 1 of the following:
!Documented hysterectomy
!Documented bilateral salpi[INVESTIGATOR_1656]
!Documented bilateral oophorectomy
Documentation can come from the site personnel’s review of the female’s medical records, 
medical examination, or medical history interview.
For a female with permanent infertility due to an alternate medical cause other than the above, 
(e.g. mullerian agenesis, androgen insensitivity), Investigator discretion applies to determine study entry.
3. A postmenopausal female
!A postmenopausal state is defined as no menses for 12 months without an alternative 
medical cause.oA high follicle-stimulating hormone (FSH) level in the postmenopausal range may be 
used to confirm a postmenopausal state in a female not using hormonal contraception or hormonal replacement therapy (HRT). However, in the absence of 12 months of amenorrhea, more than 1 FSH measurement is required in the postmenopausal range.
!A female on HRT and whose menopausal status is in doubt will be required to use one of 
the non-estrogen hormonal highly effective contraception methods if she wishes to continue her HRT during the study. Otherwise, she must discontinue HRT to allow confirmation of postmenopausal status before study enrollment.
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N94/122CONTRACEPTIVES ALLOWED DURING THE STUDY INCLUDE:
Highly Effective Methods That Have Low User Dependency
Implantable progestogen-only hormone contraception associated with inhibition of ovulation
Intrauterine device (IUD)
Intrauterine hormone-releasing system (IUS)
Bilateral tubal occlusionVasectomized partner: a highly effective contraceptive method provided that the partner is the sole sexual partner of a woman of childbearing potential and the absence of sperm has been confirmed. Otherwise, use an additional 
highly effective method of contraception. The spermatogenesis cycle is approximately 90 days.
Highly Effective Methods That Are User Dependent
!Combined (estrogen- and progestogen-containing) hormonal contraception associated with inhibition of 
ovulation
Oral
Intravaginal
TransdermalInjectable
!Progestogen-only hormone contraception associated with inhibition of ovulation
Oral
Injectable
!Sexual abstinence: a highly effective method only if defined as refraining from intercourse during the entire 
period of risk associated with the study intervention. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study.
Notes:
Contraceptive use by [CONTACT_250010].
Highly effective methods are those with a failure rate of < 1% per year when used consistently and correctly. 
Typi[INVESTIGATOR_107921].
Hormonal contraception may be susceptible to interaction with the study intervention(s), which may reduce the 
efficacy of the contraceptive method. As such, male condoms must be used in addition to hormonal 
contraception.”. If locally required, in accordance with Clinical Trial Facilitation Group (CTFG) guidelines, 
acceptable contraceptive methods are limited to those which inhibit ovulation as the primary mode of action.
Periodic abstinence (calendar, symptothermal, postovulation methods), withdrawal (coitus interruptus), 
spermicides only, and lactational amenorrhoea method (LAM) are notacceptable methods of contraception for 
this study. Male condom and female condom cannot be used together (due to risk of failure with friction).
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N95/122Appendix 4 Radiation Therapy
Radiation therapy general techniques
Linear accelerators with a minimum energy of 6MV photons will be used. A multiple-field 
technique using intensity modulated RT is highly recommended. Radiation will be delivered 5 business days/week, once per day, at 1.8 Gy/day. 
Radiation simulation and immobilization
Prior to RT, simulation utilizing CT-based planning with ≤[ADDRESS_303869]. If prone positioning is not tolerable for the participant, the supi[INVESTIGATOR_249970], if tolerable (participants drink 500 mL of water 1 h prior to scanning and 1 h prior to daily treatment). A suitable immobilization device (such as Aquaplast mold or Alphacradle) should be used with supi[INVESTIGATOR_179413].
Oral contrast is recommended to help aid in the identification of the small bowel.Intravenous contrast can be administered to participants without contrast allergy or compromised 
kidney function, depending on the clinical scenario.
A radio-opaque marker should be placed at the anal verge. 
Contouring and target volume delineation 
The following areas should be contoured:
!GTV-Pprimary gross tumor volume
!GTV-Nnodal gross tumor volume
!Clinical target volume (CTV) (50 or 50.4) should include the gross tumor volume (GTV)
with up to a 2 to 3 cm superior and inferior margin including the entire rectum, mesorectum, and presacral space.  
!CTV45should include the entire rectum, mesorectum, perirectal nodes, presacral nodes, 
internal iliac nodes, and common iliac nodes below the L5-S1 junction. 
oIn participants with T4 disease with anterior involvement of an adjacent organ (i.e. prostate, 
cervix, bladder, and vagina) the external iliac lymph nodes should be added. 
oIn participants with disease within 2 cm of the anal verge the inguinal lymph nodes and 
external iliac lymph nodes should be added. 
!The planning target volume (PTV) [ADDRESS_303870] of a 5 mm expansion around the CTV: 50.4 or CTV50 and CTV45, respectively, to compensate for inter and intrafraction uncertainly. 
!Organs at risk (OAR) should include: cauda equina, anus, rectum, large intestinal, small intestine, vagina, external genitalia, bladder, and femoral heads. 
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N96/122!Involved OARs should be delineated for treatment planning and dose volume histograms 
documentation.
!The International consensus guidelines on Clinical Target Volume for delineation in rectal cancer (Valentini 2016)  provides detailed consensus contouring descriptions that can serve as 
a guide.  
Treatment planning techniques
All treatment planning will be performed with computerized dosimetry and the dose should be 
prescribed to the isodose line that covers the treatment volume at risk.
!A single intensity modulated RT or a volumetric modulated arc therapy plan may involve 1.8 Gy to PTV45 and 2.0 Gy (111% isodose line) to PTV50 for a total of 25 fractions, if applicable.
!No hot spot of dose above 110% should be accepted beyond PTV.
!Alternatively, the PTV45 and PTV50.[ADDRESS_303871] be delineated if involved in the treated area.
Radiation therapy review/quality control
Within [ADDRESS_303872] be submitted 
to a local Quality Assuran ce body in line with institutional guidelines including:
!Pretreatment CT and MRI reports and images identifying the location of the primary rectal 
tumor
!Isodose distributions for the composite treatment plan in the axial, sagittal, and coronal planes.
oThe PTV, isocenter, and normalization method must be clearly indicated.Organs
PTV Small IntestineLarge Intestine (Outside 
of Rectum)Femur Head
Dmax< 110% Dmax<5 0G y D max< 50 D max<4 5G y
D95 > 95% V45 < 30 cc V45 < 30cc V45 < 5 cc
Bladder External genitalia Cauda
V40 < 35% V20 < 50% D max<5 0G y
V30 < 50% V30 < 20%
Dmax=maximum diameter, PTV=planning target volume.
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N97/122!Dose volume histograms for the composite treatment plan for all target volumes and required 
OAR. 
During RT, daily image guidance with orthogonal kilovoltage imaging is recommended, but is not 
required, to ensure patient position alignment during treatment and accurate targeting of the tumor and draining lymph node regions. 
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N98/122Appendix [ADDRESS_303873] practice per institutional guidelines.MethodProgressive 
DiseaseStable Disease or Partial 
ResponseNearly Complete 
Response Complete Response
Endoscopy Increase in 
tumor sizePartial response or no 
change in size!Irregular mucosa
!Small mucosal nodules 
or minor mucosal abnormality
!Superficial ulceration
!Mild persisting 
erythema of the scar!Flat, white scar
!Telangiectasia
!No ulcer
!No nodularity
Digital rectal 
examPalpable 
tumorPalpable tumor Smooth induration or minor 
mucosal abnormalitiesNormal
MRI-T2W Increase in 
tumor size!No change in extent of 
T2 scar if present or 
further regression in 
thickness of T2 scar or intermediate tumor.
!No new immediate 
signal not thought to be mural edema.
!Stable or further 
decrease in nodal size (no new nodes) !Mostly dark T2 signal
!Some remaining 
intermediate signal 
AND/OR 
!Partial regression of 
lymph nodes!Normal appearing 
bowel wall without 
any fibrosis in the 
tumor bed  
!Only dark T2 signal, 
no intermediate T2 
signal
!No visible lymph 
nodes or very few, 
small (< 5 mm nodes)
MRI=magnetic resonance imaging.
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N99/122Table 16 Response Criteria After Chemoradiation and Restaging Before Surgery
MethodProgressive 
Disease Incomplete responseNearly Complete 
Response Complete Response
Endoscopy Increase in 
tumor sizeVisible tumor !Irregular mucosa
!Small mucosal nodules
!Superficial ulceration
!Mild persisting 
erythema of the scar!Flat whitish scar
!Telangiectasia
!No ulcer
!No nodularity
Digital rectal 
examPalpable 
tumorPalpable tumor nodules Smooth induration or 
minor mucosal abnormalities Normal 
MRI-T2W Increase in 
tumor size!More intermediate 
than dark T2 signal,
!no T2 scar 
AND/OR
!No regression of 
lymph nodes!Mostly dark T2 signal, 
!Some remaining 
intermediate signal
AND/OR
!Partial regression of 
lymph nodes!Normal appearing 
bowel wall without any fibrosis in the tumor bed.
!Only dark T2 signal, 
no intermediate T2 signal.
!No visible lymph 
nodes or very few, 
small (< 5 mm nodes)
MRI=magnetic resonance imaging.
All participants, including those not undertaking surgery after chemoradiation are expected to 
continue loco-regional status evaluation (Table 17,  MRI and optional Endoscopy/Digital), until 
progressive disease, at the frequency described in Section 8.1.2 and the SoA (Table 2) for 
Long-term Follow-up evaluations (Week 27, thereafter every 3 months in Year 1: Weeks 39 and 52).
Table [ADDRESS_303874] !Local recurrence
AND/ OR
!distant recurrence!No evidence of disease
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N100/122Appendix 6 Pathology Assessments
!Grading of quality and completeness of the mesorectum in a TME
Mesorectum Defects Coning CRM
Complete Intact, smoothNot deeper than 
5m mNone Smooth, regular
Nearly completeModerate bulk, 
irregularNo visible 
muscularis propriaModerate Irregular
Incomplete Little bulkDown to the 
muscularis propriaModerate/ marked Irregular
!Definition of surgical margin status
oMargin Type
Proximal margins The proximal surgical margin refers to the most cephalad portion of the specimen (i.e.
closest to participants’s head)
Distal marginsThe distal margin refers to the most caudad portion (i.e. closest to participant’s anus)
Radial margins The radial margin, synonymously termed circumferential margin refers to the outer 
circumference of the rectal specimen
oMargin positivity
Positive A surgical margin is positive if the pathologist notes tumor within ≤[ADDRESS_303875] notes tumor > 1 but ≤[ADDRESS_303876] notes there is no tumor within 3 mm of 
any edge of the primary tumor specimen
!Overall completeness of TME resection
oThe AJCC 8th edition will be used to categorize the completeness of the TME resection. 
R0 resection All gross disease has been removed and microscopic examination reveals all surgical 
margins free of tumor. This must include the proximal, distal, and radial margin. Tumor 
> 1 mm from the tumor resection margins is considered R0.
R1 resectionThere is evidence of tumor cells at 1 or more surgical resection margin based on 
microscopic pathologic assessment of the tumor specimen but there is no macroscopic 
evidence of tumor at any resection margin nor is there macroscopic evidence of residual tumor based on the surgeon’s operative report
R2 resectionThe surgical pathologist identifies any macroscopic evidence of tumor at any of the 
surgical resection margins or there is macroscopic evidence of residual tumor based on 
the surgeon’s operative report
No resectionRemoval of the primary tumor was not performed
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N101/122oPathology TNM staging: After TME resection, pa rticipants will be staged according to AJCC 
8th edition.
T describes how far the main (primary) tumor has grown into the wall of the intestine and 
whether it has grown into nearby [CONTACT_250011]. Because this information will be ascertained from the surgical pathology report it is denoted with a prefix “p”. Because it is ascertained 
after neoadjuvant treatment, the prefix “y” is also added (i.e. ypTx).
Tx Primary tumor cannot be assessed
T0No evidence of primary tumor
TisCarcinoma in situ, intramucosal carcinoma (involvement of lamina propia with no extension 
through muscularis mucosae)
T1Tumor invades the submucosa (through the muscularis mucosa but not into the muscularis 
propria)
T2Tumor invades the muscularis propria
T3Tumor invades through the muscularis propria into pericolorectal tissues
T4aTumor invades the visceral peritoneum (including gross perforation of the bowel through tumor 
and continuous invasion of tumor through area of inflammation to the surface of the visceral 
peritoneum)
T4bTumor directly invades or adheres to adjacent organ or structures
N describes the extent of spread to nearby (regional) lymph nodes based on rectal 
resection specimen. The prefix “yp” is added as described above.
Nx Regional lymph nodes cannot be assessed
N0No regional lymph node metastasis 
N1a1 regional lymph node is positive
N1b2 or 3 regional lymph nodes are positive.
N1cNo regional lymph nodes are positive, but there are tumor deposits in the:
!Subserosa
!Mesentary
!Non-peritonealized pericolic, or perirectal/ mesorectal tissues
N2a4 to 6 regional lymph nodes are positive.
N2b7 or more regional lymph nodes are positive. 
M describes the extent of spread to distant sites outside the pelvis
M0 No distant metastasis outside the pelvis
M1aMetastasis to 1 site or organ is identified without peritoneal metastasis
M1bMetastasis to 2 or more sites or organs is identified without peritoneal metastasis
M1cMetastasis to the peritoneal surface is identified alone or with other site or organ metastasis
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N102/122Pathologic AJCC 8th Edition staging summary
When T is… and N is… and M is… Stage group is
TisN0 M0 0
T1, T2N0 M0 I
T3N0 M0 IIA
T4aN0 M0 IIB
T4bN0 M0 IIC
T1-T2N1/N1c M0 IIIA
T1N2a M0 IIIA
T3-T4aN1/N1c M0 IIIB
T2-T3N2a M0 IIIB
T1-T2bN2b M0 IIIB
T4aN2a M0 IIIC
T3-T4aN2b M0 IIIC
T4bN1-N2 M0 IIIC
Any TAny N M1a IVa
Any TAny N M1b IVb
Any TAny N M1c IVc
!Degree of pathological treatment response
oPathologic treatment response will be based on the assessment of the surgical specimen at 
the primary treatment site. 
oModified Ryan scheme for tumor regression score.
DescriptionTumor regression score
No viable cancer cells (complete response)0
Single cells or rare small groups of cancer cells (near-complete response)1
Residual cancer with evident tumor regression, but more than single cells or 
rare small groups of cancer cells (partial response)2
Extensive residual cancer with no evident tumor regression (poor or no 
response)3
!Pathological complete response (pCR)
oA pCR must include no gross or microscopic tumor identified anywhere within the surgical 
specimen. This must include both:
No evidence of malignant cells in the primary tumor specimen
AND
No evidence of malignant cells in the lymph nodes
!Pathological response other than a pathological complete response
oThe definition of non-pCR will include any surgical specimen that has any evidence of 
residual tumor manifest in the primary or regional lymph nodes
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N103/122Appendix 7 Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow-up, and Reporting
Definitions
Adverse Event
An adverse event (AE) is any untoward medical occurrence in a participant administered a 
pharmaceutical product, regardless of causal relationship with this treatment. Therefore, an AE can be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, regardless if it is considered related to the medicinal product.
For surgical or diagnostic procedures, the condition/illness leading to such a procedure is 
considered as the AE rather than the procedure itself.
The Investigator is required to grade the severity or toxicity of each AE.Investigators will reference the NCI-CTCAE, version 5.0 (publication date: 27 November 2017), 
a descriptive terminology that can be used for AE reporting.
A general grading (severity/intensity; hereafter referred to as severity) scale is provided at the 
beginning of the above referenced document, and specific event grades are also provided.
If the severity for an AE is not specifically graded by [CONTACT_12134]-CTCAE, the Investigator is to use the 
general NCI-CTCAE definitions of Grade [ADDRESS_303877] medical 
judgment.
The 5 general grades are:
!Grade 1 or Mild
!Grade 2 or Moderate
!Grade 3 or Severe
!Grade 4 or Life-threatening
!Grade [ADDRESS_303878] also be reported as an SAE. However, a 
laboratory abnormality of Grade 4, such as anemia or neutropenia, is considered serious only if the condition meets one of the serious criteria specified below.
If death occurs, the primary cause of death or event leading to death should be recorded and 
reported as an SAE. “Fatal” will be recorded as the outcome of this specific event and death will not be recorded as separate event. Only, if no cause of death can be reported (e.g. sudden death, unexplained death), the death per se might then be reported as an SAE.
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N104/122Investigators must also systematically  assess the causal relationship of AEs to study intervention 
(including any other nonstudy interventions, radiation therapy) using the following definitions. Decisive factors for the assessment of causal relationship of an AE to the study interventioninclude, but may not be limited to, temporal relationship between the AE and the study intervention, known side effects of study intervention, medical history, concomitant medication, course of the underlying disease, and study procedures.
Unrelated: Not reasonably related to the study intervention. AE could not medically 
(pharmacologically/clinically) be attributed to the study intervention under study in this clinical study protocol. A reasonable alternative explanation must be available.
Related: Reasonably related to the study intervention. AE could medically 
(pharmacologically/clinically) be attributed to the study intervention under study in this clinical study protocol.
Abnormal Laboratory Findings and Other Abnormal Investigational Findings
Abnormal laboratory findings and other abnormal investigational findings (e.g. on an ECG trace) 
should not be reported as AEs unless they are associated with clinical signs and symptoms, lead to study intervention discontinuation or are considered otherwise medically important by [CONTACT_737]. If a laboratory abnormality fulfills these criteria, the identified medical condition (e.g.anemia or increased alanine aminotransferase) must be reported as the AE rather than the abnormal value itself.
Serious Adverse Events
An SAE is any untoward medical occurrence that at any dose:
!Results in death
!Is life-threatening. Life-threatening re fers to an event in which the participant is at risk of death 
at the time of the event, not an event that hypothetically might have caused death if it was more severe
!Requires inpatient hospi[INVESTIGATOR_43928]
!Results in persistent or significant disability or incapacity
!Is a congenital anomaly or birth defect
!Is otherwise considered to be medically important. Important medical events that may not result in death, be life-threatening, or require hospi[INVESTIGATOR_249971], based 
upon appropriate medical judgment, they may jeopardize the participant or may require medical or surgical intervention to prevent one of the outcomes listed above. Examples of such events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient hospi[INVESTIGATOR_059], or the development of drug dependency or drug abuse.
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N105/122For the purposes of reporting, any suspected transmission of an infectious agent via a study 
intervention is also considered an SAE, as specified below for reporting SAEs, AEs of special interest and DLTs.
Events that Do Not Meet the Definition of an SAE
Elective hospi[INVESTIGATOR_43930], or to simplify study intervention or procedures (e.g. an 
overnight stay to facilitate intravenous therapy) are not considered SAEs. However, all events leading to unplanned hospi[INVESTIGATOR_43931] (i.e.undesirable effects of any administered treatment) must be documented and reported as SAEs.
Events Not to Be Considered as AEs/SAEs
Medical conditions present at the initial study visit that do not worsen in severity or frequency 
during the study are defined as Baseline Medical Conditions and are not to be considered AEs.
AE/SAEs Observed in Association with Disease Progression
Progression of the disease/disorder being studied assessed by [CONTACT_108133] (including laboratory abnormalities) should not be reported as an (S)AE, unless the participant’s general condition is more severe than expected for the participant’s condition and/or unless the outcome is fatal within the AE reporting period, as defined in Section 8.3.2 (Method of Detecting Adverse 
Events and Serious Adverse Events).
Adverse Events of Special Interest
For peposertib no AEs of special interest have been defined so far. Specific toxicities identified 
during the conduct of the study will be closely monitored and specific instructions for monitoring and management of expected toxicities will be incorporated into the protocol and the Investigator’s Brochure. When further safety data for this study  intervention combination will become available, 
risk assessment and mitigation activities will be reviewed to assess the continued appropriateness.
Recording and Follow-up of AE and/or SAE
It is important that each AE report include a description of the event, its duration (onset and 
resolution dates and also onset and resolution times, when it is important to assess the time of AE onset relative to the recorded study intervention administration time), its severity, its causal relationship with the study intervention, any other potential causal factors, any treatment given or other action taken, including dose modification or discontinuation of the study intervention, and its outcome. In addition, serious cases should be identified, and the appropriate seriousness criteria documented. If an AE constitutes a DLT this is documented accordingly.
Specific guidance is in the CRF Completion and Monitoring Conventions provided by [CONTACT_1034].
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N106/122Reporting Serious Adverse Events and Dose Limiting Toxicities
Serious Adverse Events
In the event of any new SAE occurring during the reporting period, the Investigator must 
immediately (within a maximum of 24 HOURS after becoming aware of the event) inform the Sponsor or its designee using the SAE Report Form in the eCRF following specific completion instructions.
Reporting of SAEs via paper Report Form is required as a back-up method only in case of 
electronic data capture failure. Names, addresses, and telephone and fax numbers will be included on the paper Report Form. All information reported via paper form must be transcribed into the eCRF as soon as the system becomes available.
In exceptional circumstances, an SAE (or follow-up information) may be reported by [CONTACT_756]; 
in these cases, an SAE Report Form must be completed immediately thereafter in the eCRF.
Relevant pages from the CRF may be provided in parallel (e.g. medical history, concomitant 
drugs). Additional documents may be provided by [CONTACT_737], if available (e.g. laboratory results, hospi[INVESTIGATOR_27450], autopsy report).
The Investigator must respond to any request for follow-up information (e.g. additional 
information, outcome, final evaluation, other records where needed) or to any question the Sponsor/designee may have on the AE within the same timelines as those noted above for initial reports. This is necessary to ensure prompt assessment of the event by [CONTACT_43971] (as applicable) to allow the Sponsor to meet strict regulatory timelines associated with expedited safety reporting obligations.
Requests for follow-up will usually be made via Study Monitor, although in exceptional 
circumstances the drug safety department may c ontact the Investigator directly to obtain further 
information or to discuss the event.
Dose Limiting Toxicities
Each event meeting the criteria of a DLT, as specified in Section 6.6.1,  must be recorded in the 
CRF within [ADDRESS_303879] be reported in an 
expedited manner as SAEs, as outlined above.
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N107/122Appendix 8 Clinical Laboratory Tests
Clinical Laboratory assessments are summarized in  Table 18.
Table 18 Protocol-Required Clinical Laboratory Assessments
Laboratory 
Assessments Parameters
Hematology Platelets Mean Corpuscular Volume:
!MCHWBC Count with 
Differential:
!Neutrophils
!Lymphocytes
!Monocytes
!Eosinophils
!BasophilsReticulocytes
Hemoglobin
Hematocrit
BiochemistryBlood Urea 
Nitrogen (BUN) PotassiumAspartate aminotransferase 
(AST) Bilirubin
Creatinine Sodium Alanine aminotransferase (ALT) Total Protein
Chloride
Glucose Calcium Alkaline phosphatase Albumin
Creatinine clearanceCreatine 
phosphokinaseLactate dehydrogenase International 
normalized ratio
Magnesium Phosphorous Activated partial thromboplastin 
time
Uric acid
Routine Urinalysis!pH, glucose, protein, blood, and ketones
!Microscopic examination (if blood or protein is abnormal) .
Other Screening 
Tests!FSH and estradiol (as needed if not a woman of childbearing potential only)
!Serum human chorionic gonadotropin (hCG) pregnancy test (as needed for women of 
childbearing potential).
ALT=alanine aminotransferase, AST=aspartate aminotransferase, BUN=blood urea nitrogen, FSH=follicle-stimulating 
hormone, hCG=human chorionic gonadotropin, MCH=mean corpuscular hemoglobin, WBC=white blood cell.
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N108/122 CCI
CCICCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N109/122Appendix 10 Model for Bayesian Dose Escalation
The Bayesian model will focus on the number of participants experiencing a DLT. The SMC will 
receive results of a Bayesian 2-parameter logistic regression model with overdose control updated with the observed DLT data (Neuenschwander 2008) .
The target toxicity is 30%. Toxicity regions are defined in  Table 19.
Table 19 Toxicity Region Definitions
Probability of DLT Loss Term (Weight in Loss Function)
Under-dosing (0.0, 0.20] 1
Targeted toxicity (0.20, 0.33] 0
Excessive toxicity (0.33, 0.60] 1
Unacceptable toxicity (0.60, 1.00] 2
DLT=dose limiting toxicity.
Recommendation on the next dose level by [CONTACT_250012]:
!Among dose levels that limit the risk of overdose (excessive or unacceptable toxicity) to a 
maximum of 25% (i.e. the 75% quantile of the estimated DLT risk at the dose level is equal to or below the lower threshold for excessive toxicity of 33%),
!Select the dose level that minimizes the loss function. The loss function is defined as the sum of products of the probability to lie within each of th e toxicity regions, and the associated loss 
term:
 (      -       )×1+ (                 )×0+ (                  )×1
+ (                     )×[ADDRESS_303880] not exceed 100% of the highest dose level considered safe at the 
time of the escalation decision.
The set of potential dose levels is (30 mg, 50 mg, 100 mg, 200 mg, 400 mg, 600 mg, 800 mg); 
however, it may be changed at any time by [CONTACT_4484]. The starting dose is 50 mg.
The SMC will be notified once the estimate for DLT probability of the MTD reaches sufficient 
precision, i.e.:
!The probability that the MTD is above highest planned dose level is > 90%,
!the probability (target toxicity) > 90%,
!or the upper bound of the 95% credible interval is lower than 40%.
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N110/122The 2-parameter logistic regression model will be set up as follows:
For a dose level d j, the relationship between dose and probability of toxicity P(DLT) is defined by:
      |  , ,  =exp  +e x p ( )×l o g   
      
1+e x p  +e x p ( )×l o g   
      
with potential dose level d j, reference dose d refand bivariate normally distributed parameters ( α,β). 
The parameters are set as follows: 
!djε {30 mg, 50 mg, 100 mg, 200 mg, 400 mg, 600 mg, 800 mg}; however, can be changed any 
time by [CONTACT_4484]
!dref= 600 mg
!E(α) = -0.847, E( β) = 0.056
!Var(α) = 3.24, Var( β) = 0.64, Cov( α, β)=0 .
The so determined prior distribution is presented in  Figure 4.
Figure 4 Prior Distribution
CI=credible interval, DLT=dose limiting toxicity.
In case information arises from other studies that changes current knowledge on the dose-toxicity 
relationship, the prior distribution will be updated prior to the first participant being treated in this 
study. This change of prior distribution will be documented in the SMC charter.
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N111/122Posterior distribution and the next dose level recommended by [CONTACT_250013] 6.4 or higher (EAST version 6.4, Cytel Inc. Copyright 2016), or R version 3.1.2 or higher with library package Bayesian continual reassessment method (Sweeting 2013) .
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N112/122Appendix 11 Protocol Amendment History
The information for the current amendment is on the title page.
Protocol Version 3.0 (11 May 2020): Overall Rationale for the Amendment
The main purpose of this protocol amendment is to provide clearer and more detailed guidance 
with regards to key therapeutic interventions, such as induction or adjuvant chemotherapy 
regimens, study treatment specifications (e.g. radiotherapy techniques), and surgical pathology 
assessment for pathological complete response. By [CONTACT_250014], the amended protocol aims at bringing more consistency in the above-mentioned procedures and is therefore expected that the variability inherent to a multi-site global study will be minimized, therefore helpi[INVESTIGATOR_249972]. The key changes are as follows: 
-Guidance for induction and adjuvant chemotherapy: in line with international guidelines 
for the treatment of rectal cancer (e.g. NCCN, ESMO), only 5-fluorouracil (5-FU) and oxaliplatin-based combination regimens (i.e. FOLFOX, or CAPEOX) will be allowed to be used for the study participants. Since the chemotherapy regimen utilized may influence outcomes, by [CONTACT_250015] 2 regimens it is expected that the interpretation of the treatment outcomes within this study (e.g. pathological response, or disease-free survival) will be subject to less variability. 
-New radiotherapy techniques such as inten sity modulated radiotherapy (IMRT) or 
volumetric-modulated arc therapy (VMAT) have been established in the clinical practice in recent years. Therefore, details about these allowed radiotherapy techniques (IMRT, VMAT and 3D) have now been included in the protocol, as well as the dose constraints for target volumes and organs at risk; as these factors play a role in the radiation tolerability, and hence may impact the study treatment safety assessment.
-The modified Ryan criteria for pathological assessment will be utilized to harmonize the 
pathological evaluation.
In addition to these changes, other relevant changes are:
-A thorax-abdomen CT scan at diagnosis for correct staging will now be mandatory and 
included at screening. Additional imaging parameters from MRI at Baseline will be described, in order to better characterize the post neoadjuvant (yTNM) tumor staging.  The presence (or absence) of extramural venous invasion (EMVI) and the circumferential margin (CRM) parameters will now be collected.
-As a result of the acquired knowledge about the PK properties of peposertib throughout the 
ongoing clinical studies, the extent of PK sampling has been minimized to reduce patient burden.
-The benefit/risk section has been updated in line with the latest update of the Investigator’s 
Brochure, resulting in the addition of new risks (rash, vomiting, diarrhea) based on nonclinical studies. It should be noted, however, that the benefit/risk assessment for the current study has not changed and remains positive. 
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N114/122Section # and Name [CONTACT_19523] 1.3 Schedule of 
Activities (Table 5)Deleted 4-h postdose PK sample 
on FD1 and FD 9 from Phase II.As this analysis will be done by [CONTACT_250016], 
this sample can be skipped to reduce the burden of the participants.
Section 2.3 Benefit/Risk AssessmentUpdated to include additional 
potential risks.For consistency with the Investigator’s 
Brochure.
Section 3 Objectives and EndpointsChanged “Genetic polymorphisms 
of genes involved in the ADME of 
peposertib” to genes involved in 
PK.For greater specificity as to what is being 
done.
Section 4.1.2 Treatment Period
Section 4.3 Justification for 
Dose
Section [IP_ADDRESS] 
RadiotherapyUpdated text to clarify RT dose of 
50 to 50.4 Gy to the tumor area.To provide more clarity on the radiotherapy 
dosage used according to NCCN guidelines.
Section 5.1 Inclusion CriteriaSpecified that FOLFOX and 
CAPEOX are allowed as inductionchemotherapi[INVESTIGATOR_014].To align with the current NCCN guidelines.
Section 6.5 Concomitant 
TherapySpecified that FOLFOX and 
CAPEOX or capecitabine are allowed as adjuvant
chemotherapi[INVESTIGATOR_014].To align with the current NCCN guidelines.
Section 6.6 Dose Selection 
and ModificationAdded statement that the selected 
RP2D and preliminary safety data from Phase Ib will be communicated to Investigators, Health Authorities and IEC/IRBs 
prior to initiating the Phase II part 
of the study, as per Sponsor’s internal communication plan.For consistency with the communication plan.
Section 8 Updated to include a maximum 
blood volume to be collected in any one-month period from each participant in the study (255 mL).To comply with new protocol template and EU 
directives.
Section 9.2 Sample Size Determination – Phase IILowered “go-criterion” for interim 
analysis.Adjustment of statistical assumptions in line 
with current results in literature.
ADME=absorption, distribution, metabolism, and excretion, CAPEOX=capecitabine and oxaliplatin, DRE=digital rectal examination, ECG=electrocardiogram, EUS=endoscopic ultrasound, FD=Fraction day, FOLFOX=Folic acid, 
5-fluorouracil, and oxaliplatin, IEC=Independent Ethics Committee, IRB=Institutional Review Board, NCCN=National 
Comprehensive Cancer Network, QTc=corrected Q-T interval, PK=pharmacokinetics, RP2D=recommended Phase II dose, RT=radiotherapy.
Administrative and editorial changes throughout for better clarity:
Section # and Name [CONTACT_250019] 1.3 Schedule of Activities (Table 1 and 2)For the visit of Wk 7 to 14 added a clarification that in case of a 
pandemic, it is per Investigator’s discretion if these visits can be done via a phone call.
Section 1.3 Schedule of Activities (Table 2) For QoL assessments modified the assessment schedule to assure 
collection of responses to questionnaires during the treatment and 
Short-term Safety FU period.  
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N117/122Section # and Name [CONTACT_250020],
Figure 1,
Figure [ADDRESS_303881] only on 
Week 14.To synchronize this evaluation with planned 
follow-up visit schedule. 
Section 4.1.1
Screening Periodand Section 8
Study Assessment and ProcedureA DRE (and EUS if indicated) and 
endoscopy will be needed at screening for participants with prior 
chemotherapy.To determine current stage before starting 
CRT, in compliance with the inclusion 
criteria.
Section 5.1
Inclusion Criteria!To allow for inclusion of 
participants with Stage II rectal cancer.!To include participants who may often 
benefit from concurrent chemoradiation according to clinical practice.
!Removed leucocyte counts in 
inclusion criterion 6.!To focus on neutrophil count as it better 
represents the WBC ability to tolerate chemoradiotherapy.
!Participants must have 
evaluable disease in both phases of the study.!Since RECIST was removed as tumor 
evaluation criteria, participants with only evaluable disease can be included.  
Section 6.5.1
Prohibited Medicines!To allow induction 
chemotherapy. 
!To allow H 2blockers under 
certain circumstances!To reflect evolving clinical practice for 
locally advanced rectal cancer.
!To improve participant’s ability to 
efficiently control adverse events.
Section 6.6 Added the option that the SMC can 
decide to decrease the dosing intensity, if needed.If M3814 dosing interruptions are necessary
due to tolerability issues, the dosing schedule can be adapted. 
Section [IP_ADDRESS]
RadiotherapyRemoved the sentence: 
“Generally, a 3 or 4 field technique should be used”.To avoid RT technique suggestion as the 
focus should be on optimal dose distribution to 
both tumor and to organs at risk. 
Section 8.[ADDRESS_303882] 1.1. Updated 
text of tumor evaluation criteria to clarify that assessments will be based on MRI, endoscopic and To update in line with current standards for 
rectal cancer evaluation in the neoadjuvant 
setting.
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N118/122Section # and Name [CONTACT_250021], per NCCN 
guideline.
Section 9.4.1 Efficacy Analysis
andTable14
Statistical Analysis Methods for Efficacy EndpointsUpdated statistical analysis 
method for “best overall response” and added statistical analysis method R0 resection.To update in line with current standards for 
rectal cancer evaluation. 
Section 9.4.1 Efficacy AnalysisAdded subgroup analyses for 
baseline characteristics, such as tumor stage.To increase clarity on planned analyses.
Schedule of Activities, 
andSection 3.1, Section 4.1.1Section 8Addition of endoscopic 
ultrasonography, if indicated or if 
performed, to the DRE assessment An endoscopic ultrasonography if indicated or 
if performed per local practice, is added to the 
assessment of palpi[INVESTIGATOR_249973]= circulating tumor DNA; DRE=digital rectal examination; FD=Fraction day; FFPE= Formalin-fixed paraffin embedded; FU=Follow up; RECIST=Response evaluation criteria in solid tumors; RT=Radiotherapy; SoA=Schedule of activities.
Administrative and editorial changes:
Section # and Name [CONTACT_19523] 1.3
Schedule of Activities
Table 5Predose sampling window updated 
to 60 min.To facilitate PK sampling schedule.
Section 2.2
BackgroundClinical study information from the 
ongoing Study EMR100036-002 and completed Study MS100036-0022 were updated.Text updated to refer to the current IB.
Section 5.1
Inclusion Criteriaand
Appendix 3Inclusion criterion #9 (male and 
female contraception) updated.To align with the current [COMPANY_006] KGaA/EMD 
Serono contraception content standards. that 
are based upon CHMP guidelines, as specified in the Clinical Study Facilitation Group (CTFG) Guidance.
Section 6.6.1 !Removed the separate 
criterion #2 and 7 from DLT definition!These criteria were redundant.
CCI
CCICCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N119/122Section # and Name [CONTACT_23688]
!Added text for drug-induced 
liver injury with Hy’s law.!To align the text language with FDA’s 
preference.
Section 6.6.3 
Management of ToxicitiesAdded a section for management 
of toxicities.To update in line with local practices.
Section 6.6.3, 
Section 6.6.3.1Diarrheaand
Section [IP_ADDRESS] 
Capecitabine Management 
for Toxicities Other Than Diarrhea
and Table 9!Added a section to mention 
the charter for diarrhea management. Removed the 
previous text for capecitabine 
dose adjustment and CTCAE grading for diarrhea from the protocol.
!Replaced thrombocytes with 
platelets in the capecitabine 
dose adjustment table.To update in line with local practices.
Section [IP_ADDRESS]
M3814 and Radiotherapy
and 
Table 11Table text updated. To clarify dose modifications of M3814 and 
radiotherapy during the study for toxicities other than diarrhea.
Section 7.1
Discontinuation of Study 
Intervention
and
Section 7.2Participant 
Discontinuation/Withdrawal 
from the StudySections updated To be in line with the current [COMPANY_006] 
KGaA/EMD Serono content standard intended for clarity and better readability.
Appendix 2
Study Governance!Text added regarding 
monitoring plan.!To update the information to align with 
the current [COMPANY_006] KGaA/EMD Serono content standards.
!Updated country list, and 
number of sites for both Phase Ib and Phase II. !To update in line with current country 
plan.
Appendix [ADDRESS_303883] laboratory evaluation 
requirement.
Throughout document Administrative, grammatical, 
typographical and punctuation changes.For clarity and better readability.
CCI
CCI
Peposertib Phase Ib/II study of peposertib in combination with capecitabine and 
MS100036-0020 radiotherapy in rectal cancer
C O N F I D E N T I A L
I N F O R M A T I O N122/122Appendix 14 Principal Investigator [INVESTIGATOR_108072]: A multicenter study with an open-label Phase Ib part 
followed by a randomized, placebo-controlled, double-blind, Phase II part to evaluate efficacy, safety, tolerability, and pharmacokinetics of the DNA-PKinhibitor peposertib (M3814) in combination with capecitabine and radiotherapy in participants with locally advanced rectal cancer
Regulatory Agency Identifying Numbers:US FDA IND 
EudraCT: 2018-002275-18
Clinical Study Protocol Version: 06 May 2021/Version 4.0
Site Number:
I am responsible for the conduct of the study at this  site, and understand and will conduct it per the 
clinical study protocol, any approved protocol amendments, International Council forHarmonisation Good Clinical Practice (Topic E6) and all applicable Health Authority requirements and national laws.
I also understand that Health Authorities may require the Sponsors of clinical studies to obtain and 
supply details about ownership interests in the Sponsor or Investigational Medicinal Product and any other financial ties with the Sponsor. The Sponsor will use any such information solely for complying with the regulatory requirements. Therefore, I agree to supply the Sponsor with any necessary information regarding ownership interest and financial ties including those of my spouse and dependent children, and to provide updates as necessary to meet Health Authority requirements.
____________________________________ ____________________________
Signature [CONTACT_108170], academic degree:
Function/Title:
Institution:
Address:
Telephone number:
Fax number:
E-mail address:
CCI
CCICCI